<html lang="en" class="pb-page js" data-request-id="94d6515ae59fa3fc-GRU"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6515ae59fa3fc-GRU">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/H4-sRv5NVu84rqJRIFMFvUrVoTGF06vOq01_ScsX-KJOys2fM0YNprbm9Q2fxON2pA_aZOnLCH3Pd1WmJLLWBQ=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6515ae59fa3fc-GRU">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.5430499138675653"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Pulmonary/Critical Care|Infectious Disease">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Viral Infections|Infectious Disease General|Global Health|Pulmonary/Critical Care General"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2015294","title":"Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome","category":"Research","type":"Original Article","topics":"Viral Infections|Infectious Disease General|Global Health|Pulmonary/Critical Care General","specialties":"Pulmonary/Critical Care|Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-10-22T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Pulmonary/Critical Care|Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Viral Infections|Infectious Disease General|Global Health|Pulmonary/Critical Care General\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2015294","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6515ae59fa3fc-GRU">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome"><meta name="dc.Creator" content="Yaseen M. Arabi"><meta name="dc.Creator" content="Ayed Y. Asiri"><meta name="dc.Creator" content="Abdullah M. Assiri"><meta name="dc.Creator" content="Hanan H. Balkhy"><meta name="dc.Creator" content="Ali Al Bshabshe"><meta name="dc.Creator" content="Majed Al Jeraisy"><meta name="dc.Creator" content="Yasser Mandourah"><meta name="dc.Creator" content="Mohamed H.A. Azzam"><meta name="dc.Creator" content="Abdulhadi M. Bin Eshaq"><meta name="dc.Creator" content="Sameera Al Johani"><meta name="dc.Creator" content="Shmeylan Al Harbi"><meta name="dc.Creator" content="Hani A.A. Jokhdar"><meta name="dc.Creator" content="Ahmad M. Deeb"><meta name="dc.Creator" content="Ziad A. Memish"><meta name="dc.Creator" content="Jesna Jose"><meta name="dc.Creator" content="Sameeh Ghazal"><meta name="dc.Creator" content="Sarah Al Faraj"><meta name="dc.Creator" content="Ghaleb A. Al Mekhlafi"><meta name="dc.Creator" content="Nisreen M. Sherbeeni"><meta name="dc.Creator" content="Fatehi E. Elzein"><meta name="dc.Creator" content="Fahad Al-Hameed"><meta name="dc.Creator" content="Asim Al Saedi"><meta name="dc.Creator" content="Naif K. Alharbi"><meta name="dc.Creator" content="Robert A. Fowler"><meta name="dc.Creator" content="Frederick G. Hayden"><meta name="dc.Creator" content="Abdulaziz Al-Dawood"><meta name="dc.Creator" content="Mohamed Abdelzaher"><meta name="dc.Creator" content="Wail Bajhmom"><meta name="dc.Creator" content="Badriah M. AlMutairi"><meta name="dc.Creator" content="Mohamed A. Hussein"><meta name="dc.Creator" content="Adel Alothman"><meta name="dc.Description" content="Whether combined treatment with recombinant interferon beta-1b and lopinavir–ritonavir reduces mortality among patients hospitalized with Middle East respiratory syndrome (MERS) is unclear.We condu..."><meta name="Description" content="Whether combined treatment with recombinant interferon beta-1b and lopinavir–ritonavir reduces mortality among patients hospitalized with Middle East respiratory syndrome (MERS) is unclear.We condu..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-10-22"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2015294"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202010223831711"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa2015294"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2015294">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2015294">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2015294">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome | NEJM">
        <meta property="og:title" content="Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2015294">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/fdebc372-176d-4a6d-a967-d5590567d359/nejmoa2015294_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/fdebc372-176d-4a6d-a967-d5590567d359/nejmoa2015294_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Whether combined treatment with recombinant interferon beta-1b and lopinavir–ritonavir
reduces mortality among patients hospitalized with Middle East respiratory syndrome
(MERS) is unclear. We cond...">
        <meta name="twitter:description" content="Whether combined treatment with recombinant interferon beta-1b and lopinavir–ritonavir
reduces mortality among patients hospitalized with Middle East respiratory syndrome
(MERS) is unclear. We cond...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2700">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2015294">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2015294">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;article:article:doi\:10.1056/NEJMoa2015294;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2020.383.issue-17;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2015294" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2015294" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2015294" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2015294" class="inputDoi"><input type="hidden" value="Y.M. Arabi and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:1645-1656" class="inputCitation"><input type="hidden" value="10-07-2020" class="inputEPubDate"><input type="hidden" value="October 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6515ae59fa3fc-GRU"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Yaseen M.</span> <span property="familyName">Arabi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ayed Y.</span> <span property="familyName">Asiri</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Abdullah M.</span> <span property="familyName">Assiri</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hanan H.</span> <span property="familyName">Balkhy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ali</span> <span property="familyName">Al Bshabshe</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Majed</span> <span property="familyName">Al Jeraisy</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yasser</span> <span property="familyName">Mandourah</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+24</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mohamed H.A.</span> <span property="familyName">Azzam</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Abdulhadi M.</span> <span property="familyName">Bin Eshaq</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7873-1159" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7873-1159</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sameera</span> <span property="familyName">Al Johani</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shmeylan</span> <span property="familyName">Al Harbi</span>, <span property="honorificSuffix">Pharm.D., B.C.P.S</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hani A.A.</span> <span property="familyName">Jokhdar</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ahmad M.</span> <span property="familyName">Deeb</span>, <span property="honorificSuffix">R.N., M.S.N.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-3680-7338" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-3680-7338</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ziad A.</span> <span property="familyName">Memish</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jesna</span> <span property="familyName">Jose</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sameeh</span> <span property="familyName">Ghazal</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sarah</span> <span property="familyName">Al Faraj</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ghaleb A.</span> <span property="familyName">Al Mekhlafi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nisreen M.</span> <span property="familyName">Sherbeeni</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fatehi E.</span> <span property="familyName">Elzein</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fahad</span> <span property="familyName">Al-Hameed</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Asim</span> <span property="familyName">Al Saedi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Naif K.</span> <span property="familyName">Alharbi</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert A.</span> <span property="familyName">Fowler</span>, <span property="honorificSuffix">M.D.C.M.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Frederick G.</span> <span property="familyName">Hayden</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Abdulaziz</span> <span property="familyName">Al-Dawood</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mohamed</span> <span property="familyName">Abdelzaher</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wail</span> <span property="familyName">Bajhmom</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Badriah M.</span> <span property="familyName">AlMutairi</span>, <span property="honorificSuffix">R.N.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mohamed A.</span> <span property="familyName">Hussein</span>, <span property="honorificSuffix">M.S.C.S., M.S.P.H., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Adel</span> <span property="familyName">Alothman</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the Saudi Critical Care Trials Group<sup><a href="#fn2" role="doc-noteref">†</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-24</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">October 7, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">1645</span>-<span property="pageEnd">1656</span></div><div class="doi">DOI: 10.1056/NEJMoa2015294</div><div class="core-enumeration"><a href="/toc/nejm/383/17"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">17</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DYaseen%2BM.%2BArabi%252C%2BAyed%2BY.%2BAsiri%252C%2BAbdullah%2BM.%2BAssiri%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D17%26contentID%3D10.1056%252FNEJMoa2015294%26title%3DInterferon%2BBeta-1b%2Band%2BLopinavir%25E2%2580%2593Ritonavir%2Bfor%2BMiddle%2BEast%2BRespiratory%2BSyndrome%26publicationDate%3D10%252F22%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2015294" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DYaseen%2BM.%2BArabi%252C%2BAyed%2BY.%2BAsiri%252C%2BAbdullah%2BM.%2BAssiri%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D17%26contentID%3D10.1056%252FNEJMoa2015294%26title%3DInterferon%2BBeta-1b%2Band%2BLopinavir%25E2%2580%2593Ritonavir%2Bfor%2BMiddle%2BEast%2BRespiratory%2BSyndrome%26publicationDate%3D10%252F22%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/28599c28-de2c-4fc2-9f3d-e1125c8c93d7/nejmoa2015294.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2015294.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2015294" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2015294" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2015294.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Whether combined treatment with recombinant interferon beta-1b and lopinavir–ritonavir reduces mortality among patients hospitalized with Middle East respiratory syndrome (MERS) is unclear.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a randomized, adaptive, double-blind, placebo-controlled trial that enrolled patients at nine sites in Saudi Arabia. Hospitalized adults with laboratory-confirmed MERS were randomly assigned to receive recombinant interferon beta-1b plus lopinavir–ritonavir (intervention) or placebo for 14 days. The primary outcome was 90-day all-cause mortality, with a one-sided P-value threshold of 0.025. Prespecified subgroup analyses and safety analyses were conducted. Because of the pandemic of coronavirus disease 2019, the data and safety monitoring board requested an unplanned interim analysis and subsequently recommended the termination of enrollment and the reporting of the results.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 95 patients were enrolled; 43 patients were assigned to the intervention group and 52 to the placebo group. A total of 12 patients (28%) in the intervention group and 23 (44%) in the placebo group died by day 90. The analysis of the primary outcome, with accounting for the adaptive design, yielded a risk difference of −19 percentage points (upper boundary of the 97.5% confidence interval [CI], −3; one-sided P=0.024). In a prespecified subgroup analysis, treatment within 7 days after symptom onset led to lower 90-day mortality than use of placebo (relative risk, 0.19; 95% CI, 0.05 to 0.75), whereas later treatment did not. Serious adverse events occurred in 4 patients (9%) in the intervention group and in 10 (19%) in the placebo group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">A combination of recombinant interferon beta-1b and lopinavir–ritonavir led to lower mortality than placebo among patients who had been hospitalized with laboratory-confirmed MERS. The effect was greatest when treatment was started within 7 days after symptom onset. (Funded by the King Abdullah International Medical Research Center; MIRACLE ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02845843" target="_blank">NCT02845843</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Over the past two decades, emerging coronaviruses (CoVs) have caused three major outbreaks — severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (Covid-19). Since MERS was reported in Saudi Arabia in 2012, at least 2494 cases and 858 associated deaths have been confirmed, with a case fatality rate of 34.4%.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Of the patients hospitalized with MERS, many have received prolonged intensive care for respiratory and other organ failure.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4 r5" id="body-ref-r5" href-manipulated="true">2-5</a></sup> Antiviral therapeutic agents of proven efficacy have been lacking.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7" id="body-ref-r7" href-manipulated="true">6,7</a></sup></div><div role="paragraph">Various formulations of recombinant interferons and lopinavir–ritonavir have been used for the treatment of MERS on the basis of preclinical and observational data on SARS and MERS.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10 r11 r12" id="body-ref-r12" href-manipulated="true">8-12</a></sup> Recombinant interferon alfa-2b has shown activity against MERS-CoV in cell culture and, in combination with ribavirin, in a rhesus macaque model of MERS-CoV infection.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10 r13" id="body-ref-r13-1" href-manipulated="true">9,10,13</a></sup> However, in some models, recombinant interferon beta has the strongest MERS-CoV inhibitory effects among various preparations of recombinant interferon agents tested in vitro.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14" id="body-ref-r14" href-manipulated="true">13,14</a></sup> Lopinavir inhibits the replication of SARS-CoV in vitro, and in one cohort of 41 patients with SARS, combination treatment with lopinavir–ritonavir and ribavirin was associated with some improvement in clinical outcomes (acute respiratory distress syndrome [ARDS] or death occurring in fewer patients), as compared with a historical control group of 111 patients who were treated with ribavirin alone.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-2" href-manipulated="true" aria-label="Reference 8">8</a></sup> Lopinavir inhibits the replication of MERS-CoV in vitro,<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> and in a marmoset model of MERS-CoV infection, treatment with either recombinant interferon beta-1b or lopinavir–ritonavir was associated with virologic, histologic, and clinical improvement as compared with control.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> The aim of the MIRACLE (MERS-CoV Infection Treated with a Combination of Lopinavir–Ritonavir and Interferon Beta-1b) trial was to investigate the efficacy of a combination of recombinant interferon beta-1b and lopinavir–ritonavir, as compared with placebo, on 90-day all-cause mortality among hospitalized patients with laboratory-confirmed MERS.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">We conducted this recursive, two-stage, group-sequential, randomized, placebo-controlled, double-blind trial at nine sites in Saudi Arabia. The trial was sponsored by the King Abdullah International Medical Research Center. The trial <a href="#ap1">protocol</a> and statistical analysis plan have been published previously<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18-1" href-manipulated="true">17,18</a></sup> and are available with the full text of this article at NEJM.org.</div><div role="paragraph">The trial protocol was designed by the management committee (see the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org) and was approved by the institutional review board at each participating site. Mobile research teams were deployed to initiate trial procedures at some sites. Data monitoring and quality checks were conducted by the management committee and the sponsor. The sponsor supported research coordinators, provided the trial medications, and provided the electronic data platform, trial monitoring, and statistical support. The management committee was responsible for the trial design and management, data analysis, and the interpretation of the results. The members of the management committee vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. The manuscript was written by the writing committee (see the <a href="#ap2">Supplementary Appendix</a>) and was approved for submission for publication by all the authors.</div></section><section id="sec-1-2"><h3>Trial Population and Regimens</h3><div role="paragraph">The trial included hospitalized patients who had MERS that had been confirmed by real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay, who were 18 years of age or older, and who had evidence of acute organ dysfunction that was judged to be related to MERS. Details of the inclusion and exclusion criteria are provided in Table S1 in the <a href="#ap2">Supplementary Appendix</a>.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-2" href-manipulated="true" aria-label="Reference 17">17</a></sup> The methods used for real-time RT-PCR testing are outlined in the <a href="#ap2">Supplementary Appendix</a>. Randomization was stratified according to center and to receipt of invasive or noninvasive mechanical ventilation (yes or no) at the time of enrollment.</div><div role="paragraph">Patients in the intervention group received recombinant interferon beta-1b (Betaferon [also called Betaseron], Bayer) as a subcutaneous injection (at a dose of 0.25 mg [8 million IU] in 1 ml of solvent) on alternate days. In addition, patients received oral lopinavir–ritonavir (at a dose of 400 mg of lopinavir and 100 mg of ritonavir; Kaletra, AbbVie) in tablet form every 12 hours. For patients who were unable to take medications by mouth, lopinavir–ritonavir (at the same dose) was administered as a 5-ml suspension every 12 hours through a nasogastric tube. Patients in the placebo group received a 1-ml subcutaneous injection of normal saline and an oral placebo that consisted of sucrose capsules (or that was administered as 5 ml of normal saline through a nasogastric tube in patients who were unable to take medications by mouth) at the same frequency as the intervention group. The intervention or placebo was administered for 14 days or until hospital discharge, whichever came first. Patients were followed daily until day 28 or hospital discharge and then at day 90. The use of intervention or placebo and the interim analyses were blinded for the research team, treating team, outcome assessors, and patients throughout the trial until the decision to conclude the trial was made according to the recommendation of the data and safety monitoring board (see below).</div></section><section id="sec-1-3"><h3>Clinical Monitoring and Outcomes</h3><div role="paragraph">We collected data on the baseline characteristics of the patients, including demographic characteristics, severity of illness, functional status as assessed with the Karnofsky performance-status score (scores range from 0 [death] to 100 [normal performance status]), coexisting conditions, and laboratory variables. During each patient’s hospitalization, we documented the administration of the trial intervention or placebo, adverse events, and laboratory data according to the published schedule.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-3" href-manipulated="true" aria-label="Reference 17">17</a></sup> Follow-up respiratory samples (nasopharyngeal swabs or, if available, sputum samples obtained from patients who were not intubated and tracheal aspirates or bronchoalveolar-lavage samples obtained from patients who were intubated) were tested by real-time RT-PCR twice weekly until two consecutive tests were negative. We collected data on cointerventions, including organ support and medications administered during the trial period.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-4" href-manipulated="true" aria-label="Reference 17">17</a></sup></div><div role="paragraph">The primary outcome was 90-day all-cause mortality. Secondary outcomes included death in the intensive care unit (ICU), in the hospital, and by day 28; days alive and free from the use of supplemental oxygen, invasive or noninvasive mechanical ventilation, renal-replacement therapy, vasopressors, extracorporeal membrane oxygenation, and organ support; and days out of the ICU in the first 28 days of the study and days of hospital stay among all patients and among patients surviving to day 90 (Table S2). We calculated serial Sequential Organ Failure Assessment (SOFA) scores. Virologic outcomes included time-to-clearance of MERS-CoV RNA and serial cycle-threshold values for the genes <i>upE</i> and <i>ORF1</i> in respiratory samples. Functional status at day 90 was assessed with the use of the Karnofsky performance-status score. Safety outcomes included reports of serious adverse events and adverse events, graded according to the Common Terminology Criteria for Adverse Events, version 4, of the National Institutes of Health (Table S3).</div></section><section id="sec-1-4"><h3>Data and Safety Monitoring Board and Interim Analyses</h3><div role="paragraph">According to the protocol, the first interim analysis was to be conducted when 34 patients had completed 90 days of follow-up.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18-2" href-manipulated="true">17,18</a></sup> At that time, the data and safety monitoring board advised that the trial be continued, and the total sample size for the trial was reestimated to be 114. Because of the Covid-19 pandemic, the data and safety monitoring board called for an unplanned interim analysis on March 15, 2020. Before performing the second analysis, the statistician on the data and safety monitoring board calculated the futility and efficacy boundaries according to the statistical analysis plan (Table S4).<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-3" href-manipulated="true" aria-label="Reference 18">18</a></sup> Although the prespecified efficacy boundaries had not been met, the data and safety monitoring board recommended on April 14, 2020, to “terminate subject enrollment and proceed with all haste in analyzing and reporting the results in peer-reviewed format” (see the letter in the <a href="#ap2">Supplementary Appendix</a>).</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">All the analyses were conducted according to the intention-to-treat principle and in accordance with the published statistical analysis plan.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19" id="body-ref-r19-1" href-manipulated="true">18,19</a></sup> Mortality at 90 days in each trial group was a combined estimate of the observed 90-day mortality in the first and second interim analyses, weighted by the inverse variance of each estimate. The absolute difference in risk was calculated as the difference in 90-day mortality between the intervention group and the placebo group. The upper boundary of the 97.5% confidence interval and one-sided P value were calculated to account for the features of the adaptive design of the trial.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19" id="body-ref-r19-2" href-manipulated="true">18,19</a></sup> We performed a crude analysis of the primary outcome that did not account for the current adaptive trial design in order to show the gain in power achieved by the use of this approach in trials of treatment for uncommon conditions, such as MERS.</div><div role="paragraph">Prespecified subgroup analyses<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18-6" href-manipulated="true">17,18</a></sup> were conducted with the use of multivariable log-binomial regression. We tested for heterogeneity of treatment effect across various subgroups and reported the corresponding P value for interaction. The subgroups were defined on the basis of time since onset of symptoms (≤7 days or &gt;7 days), the score on the Acute Physiology and Chronic Health Evaluation (APACHE) II (&gt;20 points or ≤20 points; scores range from 0 to 71, with higher scores indicating more severe disease and a higher risk of death), use of mechanical ventilation (yes or no), receipt of vasopressor therapy (yes or no), and receipt of renal-replacement therapy (yes or no).</div><div role="paragraph">The primary outcome analysis was one-sided with a type I error of 2.5%.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-7" href-manipulated="true" aria-label="Reference 18">18</a></sup> All the other analyses were two-sided with a type I error of 5%. To adjust for multiple testing for the secondary analyses, we reported the false discovery rate.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r20" id="body-ref-r20" href-manipulated="true">18,20</a></sup> All the analyses were conducted with the use of SAS software, version 9.4 (SAS Institute).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">From November 2016 through April 2020, we assessed 182 patients, of whom 96 were enrolled and underwent randomization. One patient in the intervention group withdrew informed consent and did not give permission for data use. Of the 95 remaining patients, 43 were assigned to receive recombinant interferon beta-1b and lopinavir–ritonavir (intervention) and 52 to receive placebo (Fig. S1 and Table S5). Among the screened patients, 58 did not meet the eligibility criteria, most commonly because of an absence of new organ dysfunction that was judged to be related to MERS (in 41 patients). Another 28 patients were eligible for the trial but were not enrolled, mainly because of a lack of informed consent (in 26 patients).</div><div role="paragraph">The patients’ baseline demographic characteristics, Karnofsky performance-status scores, coexisting conditions, severity-of-illness measures, and organ support and laboratory variables were similar in the two trial groups (<a href="#t1">Table 1</a> and Table S6). At the time of enrollment, 18 patients (42%) in the intervention group and 21 patients (40%) in the placebo group were receiving invasive or noninvasive mechanical ventilation.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t1.jpg"><img src="/cms/10.1056/NEJMoa2015294/asset/ad0934e8-b6dc-4f30-ab6f-54fb8bea72c0/assets/images/large/nejmoa2015294_t1.jpg" height="2912" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Intervention Group<br>(N=43)</th><th class="txxr-borders">Placebo Group<br>(N=52)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">56 (43–67)</td><td class="xxxr-borders shading">56 (43.5–67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">31 (72)</td><td class="xxxr-borders">44 (85)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Body-mass index</td><td class="xxxx-borders shading">28.3±5.5</td><td class="xxxr-borders shading">27.2±5.7</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Acquisition of MERS — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Community-acquired acquisition</td><td class="xxxx-borders shading">28 (65)</td><td class="xxxr-borders shading">38 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nosocomial acquisition</td><td class="xxxx-borders">15 (35)</td><td class="xxxr-borders">14 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Coinfection with any other virus or bacterium — no. (%)</td><td class="xxxx-borders shading">6 (14)</td><td class="xxxr-borders shading">7 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">APACHE II score<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">19.1±10.4</td><td class="xxxr-borders">20.4±11.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median SOFA score (IQR)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">6 (3–9)</td><td class="xxxr-borders shading">6 (3–9.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median Karnofsky performance-status score (IQR)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">90 (70–100)</td><td class="xxxr-borders">100 (80–100)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Coexisting conditions — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any chronic coexisting condition</td><td class="xxxx-borders">38 (88)</td><td class="xxxr-borders">45 (87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Chronic cardiac disease</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxr-borders shading">13 (25)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Chronic pulmonary disease</td><td class="xxxx-borders">3 (7)</td><td class="xxxr-borders">2 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Chronic renal disease</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxr-borders shading">15 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diabetes with chronic complications</td><td class="xxxx-borders">18 (42)</td><td class="xxxr-borders">17 (33)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Location at time of randomization — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Ward</td><td class="xxxx-borders">14 (33)</td><td class="xxxr-borders">13 (25)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">ICU</td><td class="xxxx-borders shading">29 (67)</td><td class="xxxr-borders shading">39 (75)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Randomization stratum — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mechanical ventilation</td><td class="xxxx-borders shading">18 (42)</td><td class="xxxr-borders shading">21 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No mechanical ventilation</td><td class="xxxx-borders">25 (58)</td><td class="xxxr-borders">31 (60)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Interventions before randomization — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Renal-replacement therapy</td><td class="xxxx-borders">10 (23)</td><td class="xxxr-borders">14 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Vasopressor therapy</td><td class="xxxx-borders shading">8 (19)</td><td class="xxxr-borders shading">12 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neuromuscular blockade</td><td class="xxxx-borders">11 (26)</td><td class="xxxr-borders">15 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glucocorticoids</td><td class="xxxx-borders shading">15 (35)</td><td class="xxxr-borders shading">15 (29)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Laboratory results before randomization — median (IQR)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Platelet count per mm<sup>3</sup></td><td class="xxxx-borders shading">181,000<br>(145,000–254,000)</td><td class="xxxr-borders shading">182,500<br>(154,000–235,000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White-cell count per mm<sup>3</sup></td><td class="xxxx-borders">6300 (5000–9000)</td><td class="xxxr-borders">6900 (4100–8900)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Lymphocyte count per mm<sup>3</sup></td><td class="xxxx-borders shading">1000 (500–1300)</td><td class="xxxr-borders shading">800 (600–1200)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Aspartate aminotransferase — U/liter</td><td class="xxxx-borders">55 (33–79)</td><td class="xxxr-borders">78 (45–114)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Alanine aminotransferase — U/liter</td><td class="xxxx-borders shading">42 (29–62)</td><td class="xxxr-borders shading">46 (22–76)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bilirubin — μmol/liter</td><td class="xxxx-borders">9 (6–12)</td><td class="xxxr-borders">9 (6–16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Creatinine — μmol/liter</td><td class="xbxx-borders shading">79 (64–202)</td><td class="xbxr-borders shading">94 (68–315)</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Patients in the intervention group received recombinant interferon beta-1b and lopinavir–ritonavir. Continuous variables were compared between the two trial groups with the use of an independent Student’s t-test or Mann–Whitney test, and categorical variables were compared with the use of a chi-square test or Fisher’s exact test. None of the baseline characteristics differed significantly between the two trial groups. Data on the following characteristics were missing as follows: on the body-mass index (the weight in kilograms divided by the square of the height in meters), for one patient in the placebo group; on the lymphocyte count, for five patients in the intervention group and three in the placebo group; on the aspartate aminotransferase level, for two and one, respectively; on the alanine aminotransferase level for one and one, respectively; and on the bilirubin level, for one in the placebo group. To convert the values for bilirubin to milligrams per deciliter, divide by 17.1. To convert the values for creatinine to milligrams per deciliter, divide by 88.4. Additional details on the baseline characteristics are provided in Table S6. ICU denotes intensive care unit, IQR interquartile range, and MERS Middle East respiratory syndrome.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores indicating more severe disease and a higher risk of death.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Scores on the Sequential Organ Failure Assessment (SOFA) range from 0 to 24, with higher scores indicating a greater degree of organ dysfunction.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Karnofsky performance-status scores range from 0 (death) to 100 (normal performance status).</div></div></div></figcaption></figure></div><div role="paragraph">The median time from illness onset to enrollment was 7 days in the intervention group and 7.5 days in the placebo group (<a href="#t2">Table 2</a>). Patients received a median of 7 doses of recombinant interferon beta-1b or 7 doses of corresponding placebo; they also received a median of 27 doses of lopinavir–ritonavir or 26 doses of corresponding placebo. Courses that were shorter than 14 days were related to early deaths or to interruption of the regimen, with elevated liver-enzyme levels being the most frequent reason for dose interruption (Table S7). During the trial period, the frequency of various cointerventions did not differ significantly between the two groups (<a href="#t2">Table 2</a> and Table S8).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t2.jpg"><img src="/cms/10.1056/NEJMoa2015294/asset/67dd325a-8d46-437a-954c-72e2e49ce726/assets/images/large/nejmoa2015294_t2.jpg" height="1404" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Intervention Group<br>(N=43)</th><th class="txxr-borders">Placebo Group<br>(N=52)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Interventions — median (IQR)</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">No. of interferon beta-1b or placebo injection doses</td><td class="xxxx-borders">7 (5–7)</td><td class="xxxr-borders">7 (4–7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">No. of lopinavir–ritonavir or placebo doses</td><td class="xxxx-borders shading">27 (14–28)</td><td class="xxxr-borders shading">26 (12.5–28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Time from onset of symptoms to randomization — days</td><td class="xxxx-borders">7 (5–11)</td><td class="xxxr-borders">7.5 (5–10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Time from admission to randomization — days</td><td class="xxxx-borders shading">2 (1–4)</td><td class="xxxr-borders shading">1 (1–3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Time from randomization to receipt of the first dose — days</td><td class="xxxx-borders">0 (0–0)</td><td class="xxxr-borders">0 (0–0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Time from the first positive RT-PCR assay to receipt of the first dose — days</td><td class="xxxx-borders shading">1 (0–3)</td><td class="xxxr-borders shading">1 (1–2.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Cointerventions</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Vasopressor therapy — no. (%)</td><td class="xxxx-borders shading">21 (49)</td><td class="xxxr-borders shading">30 (58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Renal-replacement therapy — no. (%)</td><td class="xxxx-borders">19 (44)</td><td class="xxxr-borders">24 (46)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Neuromuscular blockade — no. (%)</td><td class="xxxx-borders shading">22 (51)</td><td class="xxxr-borders shading">28 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Invasive mechanical ventilation — no. (%)</td><td class="xxxx-borders">26 (60)</td><td class="xxxr-borders">35 (67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Noninvasive mechanical ventilation — no. (%)</td><td class="xxxx-borders shading">4 (9)</td><td class="xxxr-borders shading">9 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Extracorporeal membrane oxygenation — no. (%)</td><td class="xxxx-borders">6 (14)</td><td class="xxxr-borders">5 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Glucocorticoids — no. (%)</td><td class="xxxx-borders shading">27 (63)</td><td class="xxxr-borders shading">31 (60)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Median duration of glucocorticoid therapy (IQR) — days<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xbxx-borders">8 (6–13)</td><td class="xbxr-borders">9 (4–18)</td></tr></tbody></table></div><figcaption><div class="caption">Interventions and Cointerventions during the Trial Period.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Continuous variables were compared between the two trial groups with the use of an independent Student’s t-test or Mann–Whitney test, and categorical variables were compared with the use of a chi-square test or Fisher’s exact test. None of the variables differed significantly between the two trial groups. Additional details on interventions and cointerventions are provided in Table S8. RT-PCR denotes reverse transcriptase–polymerase chain reaction.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The analysis of duration of glucocorticoid therapy included only patients who received a glucocorticoid.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Primary Outcome</h3><div role="paragraph">Death from any cause at 90 days occurred in 12 patients (28%) in the intervention group and in 23 patients (44%) in the placebo group. The analysis of the primary outcome (90-day mortality) that accounted for the adaptive design yielded a risk difference of −19 percentage points (upper boundary of the 97.5% confidence interval [CI], −3; one-sided P=0.024) (<a href="#f1">Figure 1A</a>, <a href="#t3">Table 3</a>, and Table S9).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2015294_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2015294_f1.jpg"><img src="/cms/10.1056/NEJMoa2015294/asset/fdebc372-176d-4a6d-a967-d5590567d359/assets/images/large/nejmoa2015294_f1.jpg" height="2700" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Probability of Survival and Subgroup Analyses.</div><div class="notes"><div role="doc-footnote">Panel A shows a Kaplan–Meier survival analysis involving all the patients enrolled in the trial. Panel B shows the results of prespecified subgroup analyses of the primary outcome (90-day all-cause mortality). Two-sided P values for interaction are reported. The false discovery rate (FDR) accounts for multiplicity by calculating the expected proportion of tests with false positives at a specified rank of a set of tests. The size of each square is proportional to the subgroup sample size. Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores indicating more severe disease and a higher risk of death.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t3.jpg"><img src="/cms/10.1056/NEJMoa2015294/asset/48a45c82-06cb-4cbe-b82c-89f636a11a1c/assets/images/large/nejmoa2015294_t3.jpg" height="917" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Intervention<br>Group<br>(N=43)</th><th class="txxx-borders">Placebo<br>Group<br>(N=52)</th><th class="txxx-borders">Risk Difference<br>(Upper Boundary of 97.5% CI)</th><th class="txxr-borders">One-Sided<br>P Value</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">percentage points</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Death by day 90 — no. (%)</td><td class="xxxx-borders shading">12 (28)</td><td class="xxxx-borders shading">23 (44)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Primary analysis: 90-day mortality — %<a href="#t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">29</td><td class="xxxx-borders">48</td><td class="xxxx-borders">−19 (−3)</td><td class="xxxr-borders">0.024</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Crude analysis: 90-day mortality — %<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xbxx-borders shading">28</td><td class="xbxx-borders shading">44</td><td class="xbxx-borders shading">−16 (3)</td><td class="xbxr-borders shading">0.05</td></tr></tbody></table></div><figcaption><div class="caption">90-Day All-Cause Mortality (Primary Outcome).</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The primary analysis accounted for the adaptive design of the trial according to the published statistical analysis plan. Mortality at 90 days in each trial group was a combined estimate of the observed 90-day mortality from the first and second interim analyses, weighted by the inverse variance of each estimate. The risk difference was calculated as the difference in 90-day mortality between the intervention group and the placebo group. The upper boundary of the 97.5% confidence interval was calculated. A one-sided P value was calculated with the use of the Z test for difference in proportion. A one-sided P value of 0.025 or less was considered to indicate statistical significance.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">A crude analysis was conducted, for illustration purposes, with the use of a Z test. The reported one-sided P value does not account for the planned stage-wise approach or for the error spending and conditional error principle used in the design of the trial, which provide more gain in power than the traditional crude approach.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-3" href-manipulated="true" aria-label="Reference 19">19</a></sup> Results of multivariate analyses are reported in Table S12.</div></div></div></figcaption></figure></div><div role="paragraph">The prespecified subgroup analysis showed that patients who had been treated within 7 days after symptom onset had lower 90-day mortality with the intervention than with placebo (relative risk, 0.19; 95% CI, 0.05 to 0.75), whereas patients who had been treated after 7 days did not (relative risk, 1.18; 95% CI, 0.63 to 2.21; P=0.006 for interaction; false discovery rate for multiple comparisons, 0.03). Across the other prespecified subgroups, there was no evidence of heterogeneity of treatment effect on the primary outcome (<a href="#f1">Figure 1B</a>).</div></section><section id="sec-2-3"><h3>Secondary Outcomes</h3><div role="paragraph">The median number of days that patients were free from invasive or noninvasive mechanical ventilation was 16 days (interquartile range, 0 to 28) in the intervention group, as compared with 5.5 days (interquartile range, 0 to 28) in the placebo group; the median number of days that patients were alive outside the ICU was 9 days (interquartile range, 0 to 28) and 0 days (interquartile range, 0 to 18), respectively. Results of other secondary outcomes are shown in <a href="#t4">Table 4</a> and Figure S2. The time to clearance of MERS-CoV RNA and the serial cycle-threshold values for the genes <i>upE</i> and <i>ORF1</i> in respiratory samples did not differ significantly between the two groups (<a href="#t4">Table 4</a> and Fig. S3). At day 90, the median Karnofsky performance-status score was 70 points (interquartile range, 0 to 100) in the intervention group and 50 points (interquartile range, 0 to 100) in the placebo group.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 4</div><nav><a href="#t4" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t4.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t4" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t4.jpg"><img src="/cms/10.1056/NEJMoa2015294/asset/4d769501-f8de-4aaf-879e-af027e03941d/assets/images/large/nejmoa2015294_t4.jpg" height="2323" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Intervention Group<br>(N=43)</th><th class="txxx-borders">Placebo Group<br>(N=52)</th><th class="txxr-borders">Relative Risk<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Death from any cause — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">By day 28</td><td class="xxxx-borders">10 (23)</td><td class="xxxx-borders">17 (33)</td><td class="xxxr-borders">0.71 (0.36–1.39)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">During ICU stay</td><td class="xxxx-borders shading">12 (28)</td><td class="xxxx-borders shading">22 (42)</td><td class="xxxr-borders shading">0.66 (0.37–1.17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">During hospital stay</td><td class="xxxx-borders">13 (30)<a href="#t4fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">23 (44)</td><td class="xxxr-borders">0.68 (0.40–1.18)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Alive at day 90 — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Receiving renal-replacement therapy</td><td class="xxxx-borders">6 (14)</td><td class="xxxx-borders">3 (6)</td><td class="xxxr-borders">2.42 (0.64–9.11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Receiving supplemental oxygen</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxr-borders shading">3.63 (0.39–33.63)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Receiving invasive mechanical ventilation</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (2)</td><td class="xxxr-borders">2.42 (0.23–25.78)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Median duration (IQR) — days<a href="#t4fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Free from supplemental oxygen therapy</td><td class="xxxx-borders">4 (0–19)</td><td class="xxxx-borders">0 (0–17)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Free from invasive or noninvasive mechanical ventilation</td><td class="xxxx-borders shading">16 (0–28)</td><td class="xxxx-borders shading">5.5 (0–28)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Free from renal-replacement therapy</td><td class="xxxx-borders">28 (7–28)</td><td class="xxxx-borders">22 (0–28)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Free from vasopressor therapy</td><td class="xxxx-borders shading">27 (3–28)</td><td class="xxxx-borders shading">24.5 (0–28)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Free from extracorporeal membrane oxygenation</td><td class="xxxx-borders">28 (0–28)</td><td class="xxxx-borders">28 (0–28)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Free from organ support</td><td class="xxxx-borders shading">15 (0–28)</td><td class="xxxx-borders shading">5 (0–27.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Outside the ICU</td><td class="xxxx-borders">9 (0–28)</td><td class="xxxx-borders">0 (0–18)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Of hospital stay</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Among all patients</td><td class="xxxx-borders">22 (11–40)</td><td class="xxxx-borders">17.5 (8–34)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Among patients surviving to 90 days</td><td class="xxxx-borders shading">26 (14–43)</td><td class="xxxx-borders shading">20 (10–37)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Virologic outcomes</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Median no. of days to MERS-CoV RNA clearance (IQR)<a href="#t4fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Among all patients</td><td class="xxxx-borders">17 (9–25)</td><td class="xxxx-borders">20 (10–33)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Among patients surviving to 90 days</td><td class="xxxx-borders shading">13 (8–21)</td><td class="xxxx-borders shading">12 (9–22)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Functional outcome</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median Karnofsky performance-status score at day 90 (IQR)<a href="#t4fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">70 (0–100)</td><td class="xxxx-borders shading">50 (0–100)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Safety outcomes</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Serious adverse event — no. (%)<a href="#t4fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">4 (9)</td><td class="xxxx-borders shading">10 (19)</td><td class="xxxr-borders shading">0.48 (0.16–1.43)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Acute pancreatitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (2)</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Elevation of alanine aminotransferase level to &gt;5× ULN</td><td class="xxxx-borders shading">4 (9)</td><td class="xxxx-borders shading">9 (17)</td><td class="xxxr-borders shading">0.54 (0.18–1.62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">Other serious adverse event</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (2)</td><td class="xbxr-borders">—</td></tr></tbody></table></div><figcaption><div class="caption">Secondary Outcomes.<a href="#t4fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t4fn1" role="paragraph">The 95% confidence intervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproducible. MERS-CoV denotes MERS coronavirus, and ULN upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t4fn2" role="paragraph">One patient in the intervention group died during the hospital stay after day 90.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t4fn3" role="paragraph">The calculations of days free from supplemental oxygen therapy, days free from mechanical ventilation, days free from renal-replacement therapy, days free from vasopressor therapy, days free from extracorporeal membrane oxygenation, days free from organ support, and days outside the ICU were based on 28 days of observation.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t4fn4" role="paragraph">Days to clearance of MERS-CoV RNA were censored by death or hospital discharge.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t4fn5" role="paragraph">Data on the Karnofsky performance-status score at day 90 were not available for one patient in the placebo group.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t4fn6" role="paragraph">P values for serious adverse events are provided in Table S10.</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Safety Outcomes</h3><div role="paragraph">Serious adverse events were reported in 4 patients (9%) in the intervention group and in 10 (19%) in the placebo group. The majority of serious adverse events were related to elevated liver-enzyme levels. The incidence of adverse events did not differ significantly between the two trial groups (Tables S10 and S11).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">We found that, among hospitalized patients with laboratory-confirmed MERS, treatment with recombinant interferon beta-1b and lopinavir–ritonavir resulted in lower 90-day mortality than use of placebo. The treatment effect was observed in patients who were treated within 7 days after symptom onset, among whom mortality was lower with the intervention than with placebo. In contrast, a similar treatment effect was not observed with later initiation of therapy. Our findings of an important time-to-treatment effect on mortality are consistent with earlier observations in patients with severe influenza who were given oseltamivir<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22 r23 r24" id="body-ref-r24" href-manipulated="true">21-24</a></sup> and with the results of a recent trial of remdesivir in patients with severe Covid-19.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup></div><div role="paragraph">A majority of patients in the intervention group received the 14-day planned course of treatment with recombinant interferon beta-1b and lopinavir–ritonavir. The incidences of interruptions in the trial regimen and of adverse events were similar in the intervention group and the placebo group, although serious adverse events were numerically more common in the placebo group than in the intervention group. Our findings suggest that these events were related to the disease rather than to the treatment with recombinant interferon beta-1b and lopinavir–ritonavir. An open-label, randomized trial of lopinavir–ritonavir in 199 patients with Covid-19 also showed that lopinavir–ritonavir monotherapy was associated with a lower incidence of serious adverse events than was observed in control patients receiving standard care, although the treatment was not associated with a significantly shorter time to clinical improvement.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup></div><div role="paragraph">One practical consideration related to our trial is the administration of lopinavir–ritonavir through a nasogastric tube in critically ill patients. The crushing of lopinavir–ritonavir tablets is associated with reduced and unpredictable bioavailability (reduction by approximately 50%; range, 5 to 75).<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup> Consequently, patients treated in the MIRACLE trial who were unable to swallow tablets received lopinavir–ritonavir as a suspension.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-7" href-manipulated="true" aria-label="Reference 17">17</a></sup> Preliminary data from the RECOVERY (Randomised Evaluation of Covid-19 Therapy) and Solidarity trials of lopinavir–ritonavir monotherapy in hospitalized patients with Covid-19 showed no significant difference in mortality, but data about the timing of the intervention are not available at this time.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28 r29" id="body-ref-r29" href-manipulated="true">28,29</a></sup></div><div role="paragraph">MERS-CoV and SARS-CoV-1, the virus that causes SARS, was found to suppress the release of interferon in preclinical studies.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30 r31 r32 r33 r34 r35" id="body-ref-r35" href-manipulated="true">30-35</a></sup> SARS-CoV-2, the virus that causes Covid-19, causes similar effects in diminishing type I and type III interferon signatures in infected primary human bronchial cells and in a ferret model.<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36" href-manipulated="true" aria-label="Reference 36">36</a></sup> Patients with severe Covid-19 have impaired type 1 interferon signatures, as compared with patients who have mild or moderate illness.<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37" id="body-ref-r37" href-manipulated="true" aria-label="Reference 37">37</a></sup> Recently, inborn errors of type 1 interferon immunity or autoantibodies against interferon alfa subtypes and, less commonly, interferon beta have been described in patients with life-threatening Covid-19.<sup><a href="#core-r38" role="doc-biblioref" data-xml-rid="r38 r39" id="body-ref-r39" href-manipulated="true">38,39</a></sup> These lines of evidence support studies of treatment with interferon beta in patients with Covid-19.</div><div role="paragraph">In a recent randomized, controlled trial, a combination of lopinavir–ritonavir, ribavirin, and recombinant interferon beta-1b alleviated symptoms and shortened the duration of viral RNA detection and hospital stay in patients with mild Covid-19, as compared with patients who received treatment with lopinavir–ritonavir alone.<sup><a href="#core-r40" role="doc-biblioref" data-xml-rid="r40" id="body-ref-r40-1" href-manipulated="true" aria-label="Reference 40">40</a></sup> In that trial, recombinant interferon beta-1b was omitted in patients who were recruited after day 7 after symptom onset because of concerns about its proinflammatory effects.<sup><a href="#core-r40" role="doc-biblioref" data-xml-rid="r40 r41 r42" id="body-ref-r42" href-manipulated="true">40-42</a></sup> Our trial showed that benefit was likely with early treatment but unlikely with later therapy. Small, randomized, controlled trials of interferon beta-1a or interferon beta-1b have suggested clinical benefit in hospitalized patients with Covid-19,<sup><a href="#core-r43" role="doc-biblioref" data-xml-rid="r43 r44" id="body-ref-r44" href-manipulated="true">43,44</a></sup> and preliminary results of a phase 2 study involving patients with mild-to-moderate Covid-19 have suggested that treatment with inhaled recombinant interferon beta-1a results in a lower risk of severe disease (involving the use of mechanical ventilation or resulting in death) than placebo.<sup><a href="#core-r45" role="doc-biblioref" data-xml-rid="r45" id="body-ref-r45" href-manipulated="true" aria-label="Reference 45">45</a></sup> Recombinant interferon beta-1a and interferon beta-1b are currently under study in patients with Covid-19 in multiple randomized, controlled trials (ClinicalTrials.gov numbers, <a href="http://clinicaltrials.gov/show/NCT04492475" target="_blank">NCT04492475</a> and <a href="http://clinicaltrials.gov/show/NCT02735707" target="_blank">NCT02735707</a>; ISRCTN Registry number, <a href="http://www.controlled-trials.com/ISRCTN83971151" target="_blank">ISRCTN83971151</a>).</div><div role="paragraph">The immunomodulatory effects of recombinant interferon beta-1b have been examined in unselected patients with moderate-to-severe ARDS.<sup><a href="#core-r46" role="doc-biblioref" data-xml-rid="r46 r47 r48" id="body-ref-r48-1" href-manipulated="true">46-48</a></sup> An early-phase, nonrandomized study showed that treatment with recombinant interferon beta-1a was associated with lower 28-day mortality than use of placebo.<sup><a href="#core-r46" role="doc-biblioref" data-xml-rid="r46" id="body-ref-r46-2" href-manipulated="true" aria-label="Reference 46">46</a></sup> A phase 3, randomized, controlled trial showed no difference between interferon beta-1a and placebo in the primary composite outcome (death and the number of ventilator-free days at day 28).<sup><a href="#core-r47" role="doc-biblioref" data-xml-rid="r47" id="body-ref-r47-2" href-manipulated="true" aria-label="Reference 47">47</a></sup> A post hoc analysis showed that use of recombinant interferon beta-1a with glucocorticoids was associated with higher mortality, whereas the administration of recombinant interferon beta-1a without glucocorticoids was not.<sup><a href="#core-r47" role="doc-biblioref" data-xml-rid="r47 r48" id="body-ref-r48-2" href-manipulated="true">47,48</a></sup> Hydrocortisone inhibits interferon beta signaling and the up-regulation of CD73 in human lung tissues ex vivo.<sup><a href="#core-r49" role="doc-biblioref" data-xml-rid="r49" id="body-ref-r49" href-manipulated="true" aria-label="Reference 49">49</a></sup> In our trial, approximately 30% of the patients were receiving glucocorticoids at the time of enrollment and another 30% did so during the course of the trial. More data are needed about the biologic interaction of glucocorticoids with recombinant interferon beta therapy in patients with Covid-19. This is especially important given the common use of glucocorticoids in patients with Covid-19 and the recent findings of a survival benefit with dexamethasone in hospitalized patients with Covid-19 who were receiving supplemental oxygen or greater levels of ventilatory support.<sup><a href="#core-r50" role="doc-biblioref" data-xml-rid="r50" id="body-ref-r50" href-manipulated="true" aria-label="Reference 50">50</a></sup></div><div role="paragraph">We did not observe accelerated viral RNA clearance with the intervention or differences between the two groups in the cycle-threshold values over time. Our virologic findings are limited by a lack of data on quantitative viral RNA detection or infectious virus isolation from lower respiratory tract samples. In one study of SARS-CoV-2 in nonhuman primates, the effect of early antiviral therapy with remdesivir appeared to be greater on infectious virus recovery in bronchoalveolar-lavage samples than on viral RNA detection in bronchoalveolar-lavage or upper respiratory tract samples.<sup><a href="#core-r51" role="doc-biblioref" data-xml-rid="r51" id="body-ref-r51" href-manipulated="true" aria-label="Reference 51">51</a></sup> It may be that prolonged viral RNA detectability in patients with MERS makes this an insensitive marker of antiviral efficacy.</div><div role="paragraph">Some of the features of the results of our trial are direct consequences of the challenges of conducting a trial involving patients with an uncommon disease that is sporadic in geographic and temporal distribution. Variation in the number of enrolled patients according to site, owing to regional distribution of cases and to some sites being assigned to be MERS referral hospitals, led to low recruitment at many sites and to a slight sample-size imbalance between the two trial groups.</div><div role="paragraph">Strengths of our trial include the randomized, double-blind, placebo-controlled design. We followed patients up to 90 days for mortality. The survival curves in our trial continued to diverge beyond day 28, which may be related to additional deaths in the placebo group as a consequence of organ failure — a result that suggests the importance of longer-term follow-up in trials of therapeutic agents for patients with severe or critical Covid-19. We followed a pragmatic approach in relation to standard of care, in order to reflect current practice and to facilitate the enrollment of patients. Because of the uncommon, episodic nature of MERS, we used a recursive two-stage design that provided flexibility to introduce sample-size adjustment while allowing for continual learning from the observed data without compromise of the overall trial type I error. Finally, a trial design with early futility boundaries provided a gain in power over the traditional approach.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19" id="body-ref-r19-4" href-manipulated="true">18,19</a></sup> Limitations of the trial include its early termination, which reduced the power. With a sample size of 95, the trial had insufficient power to detect differences in secondary analyses. An inherent problem of adaptive designs is that early stopping might lead to overestimation of the treatment effect.</div><div role="paragraph">In this trial involving hospitalized patients with laboratory-confirmed MERS, we found that combination therapy with recombinant interferon beta-1b and lopinavir–ritonavir led to lower mortality at 90 days than placebo. The effect was greatest when treatment was started within 7 days after symptom onset.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on October 7, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by the <span class="named-content" data-type="funder">King Abdullah International Medical Research Center</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">This article is dedicated to the memory of Dr. Adel Alothman, clinician and colleague, who died unexpectedly during the preparation of this article.</div><div role="paragraph">We thank all the participating patients and their families, as well as the members of the data and safety monitoring board: Greg S. Martin, M.D. (chair), David A. Schoenfeld, Ph.D., Sharon L. Walmsley, M.D., and Shannon Carson, M.D.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2015294_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2015294/suppl_file/nejmoa2015294_protocol.pdf" download="nejmoa2015294_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2015294_protocol.pdf" data-doi="10.1056/NEJMoa2015294">Download</a></li><li>2.92 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2015294_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2015294/suppl_file/nejmoa2015294_appendix.pdf" download="nejmoa2015294_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2015294_appendix.pdf" data-doi="10.1056/NEJMoa2015294">Download</a></li><li>3.35 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2015294_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2015294/suppl_file/nejmoa2015294_disclosures.pdf" download="nejmoa2015294_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2015294_disclosures.pdf" data-doi="10.1056/NEJMoa2015294">Download</a></li><li>569.30 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2015294_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2015294/suppl_file/nejmoa2015294_data-sharing.pdf" download="nejmoa2015294_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2015294_data-sharing.pdf" data-doi="10.1056/NEJMoa2015294">Download</a></li><li>70.75 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). 2019 (<a href="https://www.who.int/emergencies/mers-cov/en/">https://www.who.int/emergencies/mers-cov/en/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=World+Health+Organization.+Middle+East+respiratory+syndrome+coronavirus+%28MERS-CoV%29.+2019+%28https%3A%2F%2Fwww.who.int%2Femergencies%2Fmers-cov%2Fen%2F%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. <em>N Engl J Med</em> 2017;376:584-594.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_6_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2015294&amp;key=10.1056%2FNEJMsr1408795&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28177862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393510500018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Middle+East+respiratory+syndrome.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=584-594&amp;doi=10.1056%2FNEJMsr1408795&amp;pmid=28177862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Al-Omari A, Mandourah Y, et al. Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. <em>Crit Care Med</em> 2017;45:1683-1695.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCM.0000000000002621" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28787295/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410960300041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Critically+ill+patients+with+the+Middle+East+respiratory+syndrome%3A+a+multicenter+retrospective+cohort+study.&amp;publication_year=2017&amp;journal=Crit+Care+Med&amp;pages=1683-1695&amp;doi=10.1097%2FCCM.0000000000002621&amp;pmid=28787295" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. <em>Lancet Infect Dis</em> 2014;14:1090-1095.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(14)70920-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25278221/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343743700034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ribavirin+and+interferon+alfa-2a+for+severe+Middle+East+respiratory+syndrome+coronavirus+infection%3A+a+retrospective+cohort+study.&amp;publication_year=2014&amp;journal=Lancet+Infect+Dis&amp;pages=1090-1095&amp;doi=10.1016%2FS1473-3099%2814%2970920-X&amp;pmid=25278221" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. <em>Lancet Infect Dis</em> 2013;13:752-761.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(13)70204-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23891402/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000323465900020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemiological%2C+demographic%2C+and+clinical+characteristics+of+47+cases+of+Middle+East+respiratory+syndrome+coronavirus+disease+from+Saudi+Arabia%3A+a+descriptive+study.&amp;publication_year=2013&amp;journal=Lancet+Infect+Dis&amp;pages=752-761&amp;doi=10.1016%2FS1473-3099%2813%2970204-4&amp;pmid=23891402" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. <em>Clin Infect Dis</em> 2020;70:1837-1844.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciz544" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31925415/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000537513500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ribavirin+and+interferon+therapy+for+critically+ill+patients+with+Middle+East+respiratory+syndrome%3A+a+multicenter+observational+study.&amp;publication_year=2020&amp;journal=Clin+Infect+Dis&amp;pages=1837-1844&amp;doi=10.1093%2Fcid%2Fciz544&amp;pmid=31925415" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Kain T, Lindsay PJ, Adhikari NKJ, Arabi YM, Van Kerkhove MD, Fowler RA. Pharmacologic treatments and supportive care for Middle East respiratory syndrome. <em>Emerg Infect Dis</em> 2020;26:1102-1112.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid2606.200037" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32213260/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000541513900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacologic+treatments+and+supportive+care+for+Middle+East+respiratory+syndrome.&amp;publication_year=2020&amp;journal=Emerg+Infect+Dis&amp;pages=1102-1112&amp;doi=10.3201%2Feid2606.200037&amp;pmid=32213260" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. <em>Thorax</em> 2004;59:252-256.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/thorax.2003.012658" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14985565/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000189217200016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Role+of+lopinavir%2Fritonavir+in+the+treatment+of+SARS%3A+initial+virological+and+clinical+findings.&amp;publication_year=2004&amp;journal=Thorax&amp;pages=252-256&amp;doi=10.1136%2Fthorax.2003.012658&amp;pmid=14985565" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and observational data on SARS and MERS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] who were treated with ribavirin alone. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. <em>Sci Rep</em> 2013;3:1686-1686.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/srep01686" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23594967/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000317643300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+novel+%CE%B2+coronavirus+replication+by+a+combination+of+interferon-%CE%B12b+and+ribavirin.&amp;publication_year=2013&amp;journal=Sci+Rep&amp;pages=1686-1686&amp;doi=10.1038%2Fsrep01686&amp;pmid=23594967" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and observational data on SARS and MERS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] rhesus macaque model of MERS-CoV infection. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. <em>Nat Med</em> 2013;19:1313-1317.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm.3362" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24013700/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325531700031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+with+interferon-%CE%B12b+and+ribavirin+improves+outcome+in+MERS-CoV-infected+rhesus+macaques.&amp;publication_year=2013&amp;journal=Nat+Med&amp;pages=1313-1317&amp;doi=10.1038%2Fnm.3362&amp;pmid=24013700" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and observational data on SARS and MERS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] rhesus macaque model of MERS-CoV infection. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV) — possible lessons from a systematic review of SARS-CoV therapy. <em>Int J Infect Dis</em> 2013;17(10):e792-8.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ijid.2013.07.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23993766/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000324476200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Therapeutic+options+for+Middle+East+respiratory+syndrome+coronavirus+%28MERS-CoV%29+%E2%80%94+possible+lessons+from+a+systematic+review+of+SARS-CoV+therapy.&amp;publication_year=2013&amp;journal=Int+J+Infect+Dis&amp;pages=e792-8&amp;doi=10.1016%2Fj.ijid.2013.07.002&amp;pmid=23993766" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. <em>PLoS Med</em> 2006;3(9):e343-e343.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.0030343" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16968120/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000241923800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS%3A+systematic+review+of+treatment+effects.&amp;publication_year=2006&amp;journal=PLoS+Med&amp;pages=e343-e343&amp;doi=10.1371%2Fjournal.pmed.0030343&amp;pmid=16968120" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. <em>J Gen Virol</em> 2014;95:571-577.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1099/vir.0.061911-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24323636/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000338177500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interferon-%CE%B2+and+mycophenolic+acid+are+potent+inhibitors+of+Middle+East+respiratory+syndrome+coronavirus+in+cell-based+assays.&amp;publication_year=2014&amp;journal=J+Gen+Virol&amp;pages=571-577&amp;doi=10.1099%2Fvir.0.061911-0&amp;pmid=24323636" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rhesus macaque model of MERS-CoV infection. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] interferon agents tested in vitro. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Chan JFW, Chan K-H, Kao RYT, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. <em>J Infect</em> 2013;67:606-616.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jinf.2013.09.029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24096239/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000326588400012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Broad-spectrum+antivirals+for+the+emerging+Middle+East+respiratory+syndrome+coronavirus.&amp;publication_year=2013&amp;journal=J+Infect&amp;pages=606-616&amp;doi=10.1016%2Fj.jinf.2013.09.029&amp;pmid=24096239" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. <em>Antimicrob Agents Chemother</em> 2014;58:4875-4884.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.03011-14" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24841269/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000339259200073" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Screening+of+an+FDA-approved+compound+library+identifies+four+small-molecule+inhibitors+of+Middle+East+respiratory+syndrome+coronavirus+replication+in+cell+culture.&amp;publication_year=2014&amp;journal=Antimicrob+Agents+Chemother&amp;pages=4875-4884&amp;doi=10.1128%2FAAC.03011-14&amp;pmid=24841269" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. <em>J Infect Dis</em> 2015;212:1904-1913.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jiv392" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26198719/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000368671500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+with+lopinavir%2Fritonavir+or+interferon-%CE%B21b+improves+outcome+of+MERS-CoV+infection+in+a+nonhuman+primate+model+of+common+marmoset.&amp;publication_year=2015&amp;journal=J+Infect+Dis&amp;pages=1904-1913&amp;doi=10.1093%2Finfdis%2Fjiv392&amp;pmid=26198719" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. <em>Trials</em> 2018;19:81-81.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13063-017-2427-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29382391/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423823900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+Middle+East+respiratory+syndrome+with+a+combination+of+lopinavir-ritonavir+and+interferon-%CE%B21b+%28MIRACLE+trial%29%3A+study+protocol+for+a+randomized+controlled+trial.&amp;publication_year=2018&amp;journal=Trials&amp;pages=81-81&amp;doi=10.1186%2Fs13063-017-2427-0&amp;pmid=29382391" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] plan have been published previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Supplementary Appendix. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] data according to the published schedule. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] administered during the trial period. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] had completed 90 days of follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] Prespecified subgroup analyses </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] lopinavir–ritonavir as a suspension. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Asiri AY, Assiri AM, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. <em>Trials</em> 2020;21:8-8.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13063-019-3846-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31900204/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000513539700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+Middle+East+respiratory+syndrome+with+a+combination+of+lopinavir%2Fritonavir+and+interferon-%CE%B21b+%28MIRACLE+trial%29%3A+statistical+analysis+plan+for+a+recursive+two-stage+group+sequential+randomized+controlled+trial.&amp;publication_year=2020&amp;journal=Trials&amp;pages=8-8&amp;doi=10.1186%2Fs13063-019-3846-x&amp;pmid=31900204" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] plan have been published previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] had completed 90 days of follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the statistical analysis plan (Table S4). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the published statistical analysis plan. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] of the adaptive design of the trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] Prespecified subgroup analyses </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] was one-sided with a type I error of 2.5%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] we reported the false discovery rate. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>i [...] in power over the traditional approach. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Chang M. Adaptive design theory and implementation using SAS and R. 2nd ed. Boca Raton, FL: Chapman &amp; Hall/CRC Press, 2014:153-180.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Chang+M.+Adaptive+design+theory+and+implementation+using+SAS+and+R.+2nd+ed.+Boca+Raton%2C+FL%3A+Chapman+%26+Hall%2FCRC+Press%2C+2014%3A153-180." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the published statistical analysis plan. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of the adaptive design of the trial. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r19-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] power than the traditional crude approach. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] in power over the traditional approach. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. <em>J R Stat Soc B</em> 1995;57:289-300.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.2517-6161.1995.tb02031.x" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1995QE45300017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Controlling+the+false+discovery+rate%3A+a+practical+and+powerful+approach+to+multiple+testing.&amp;publication_year=1995&amp;journal=J+R+Stat+Soc+B&amp;pages=289-300&amp;doi=10.1111%2Fj.2517-6161.1995.tb02031.x" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Katzen J, Kohn R, Houk JL, Ison MG. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. <em>Clin Infect Dis</em> 2019;69:52-58.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciy860" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30304487/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000485166800007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+oseltamivir+after+hospital+admission+is+associated+with+shortened+hospitalization%3A+a+5-year+analysis+of+oseltamivir+timing+and+clinical+outcomes.&amp;publication_year=2019&amp;journal=Clin+Infect+Dis&amp;pages=52-58&amp;doi=10.1093%2Fcid%2Fciy860&amp;pmid=30304487" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <em>Lancet Respir Med</em> 2014;2:395-404.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(14)70041-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24815805/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336716300022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+neuraminidase+inhibitors+in+reducing+mortality+in+patients+admitted+to+hospital+with+influenza+A+H1N1pdm09+virus+infection%3A+a+meta-analysis+of+individual+participant+data.&amp;publication_year=2014&amp;journal=Lancet+Respir+Med&amp;pages=395-404&amp;doi=10.1016%2FS2213-2600%2814%2970041-4&amp;pmid=24815805" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Hernu R, Chroboczek T, Madelaine T, et al. Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysis. <em>Intensive Care Med</em> 2018;44:257-260.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00134-017-4953-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29026934/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425330000020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+oseltamivir+therapy+improves+the+outcome+in+critically+ill+patients+with+influenza%3A+a+propensity+analysis.&amp;publication_year=2018&amp;journal=Intensive+Care+Med&amp;pages=257-260&amp;doi=10.1007%2Fs00134-017-4953-3&amp;pmid=29026934" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Chan PKS, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. <em>J Infect Dis</em> 2012;206:1359-1366.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jis509" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22927451/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309930700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determinants+of+antiviral+effectiveness+in+influenza+virus+A+subtype+H5N1.&amp;publication_year=2012&amp;journal=J+Infect+Dis&amp;pages=1359-1366&amp;doi=10.1093%2Finfdis%2Fjis509&amp;pmid=22927451" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <em>Lancet</em> 2020;395:1569-1578.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)31022-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32423584/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000536542900023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Remdesivir+in+adults+with+severe+COVID-19%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+multicentre+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1569-1578&amp;doi=10.1016%2FS0140-6736%2820%2931022-9&amp;pmid=32423584" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. <em>N Engl J Med</em> 2020;382:1787-1799.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_6_27_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2015294&amp;key=10.1056%2FNEJMoa2001282&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32187464/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000533411000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+trial+of+lopinavir%E2%80%93ritonavir+in+adults+hospitalized+with+severe+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1787-1799&amp;doi=10.1056%2FNEJMoa2001282&amp;pmid=32187464" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Best BM, Capparelli EV, Diep H, et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. <em>J Acquir Immune Defic Syndr</em> 2011;58:385-391.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0b013e318232b057" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21876444/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296920900015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetics+of+lopinavir%2Fritonavir+crushed+versus+whole+tablets+in+children.&amp;publication_year=2011&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=385-391&amp;doi=10.1097%2FQAI.0b013e318232b057&amp;pmid=21876444" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir. June 29, 2020 (<a href="https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf">https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Statement+from+the+Chief+Investigators+of+the+Randomised+Evaluation+of+COVid-19+thERapY+%28RECOVERY%29+Trial+on+lopinavir-ritonavir.+June+29%2C+2020+%28https%3A%2F%2Fwww.recoverytrial.net%2Ffiles%2Flopinavir-ritonavir-recovery-statement-29062020_final.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. July 4, 2020 (<a href="https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19">https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=World+Health+Organization.+WHO+discontinues+hydroxychloroquine+and+lopinavir%2Fritonavir+treatment+arms+for+COVID-19.+July+4%2C+2020+%28https%3A%2F%2Fwww.who.int%2Fnews-room%2Fdetail%2F04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Cameron MJ, Kelvin AA, Leon AJ, et al. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. <em>PLoS One</em> 2012;7(9):e45842-e45842.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0045842" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23029269/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309554700077" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lack+of+innate+interferon+responses+during+SARS+coronavirus+infection+in+a+vaccination+and+reinfection+ferret+model.&amp;publication_year=2012&amp;journal=PLoS+One&amp;pages=e45842-e45842&amp;doi=10.1371%2Fjournal.pone.0045842&amp;pmid=23029269" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. <em>PLoS One</em> 2009;4(12):e8342-e8342.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0008342" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20020050/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272834200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+SARS+Coronavirus+3a+protein+causes+endoplasmic+reticulum+stress+and+induces+ligand-independent+downregulation+of+the+type+1+interferon+receptor.&amp;publication_year=2009&amp;journal=PLoS+One&amp;pages=e8342-e8342&amp;doi=10.1371%2Fjournal.pone.0008342&amp;pmid=20020050" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Siu K-L, Chan C-P, Kok K-H, Woo PC-Y, Jin D-Y. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. <em>Cell Mol Immunol</em> 2014;11:141-149.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/cmi.2013.61" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24509444/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000332471400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suppression+of+innate+antiviral+response+by+severe+acute+respiratory+syndrome+coronavirus+M+protein+is+mediated+through+the+first+transmembrane+domain.&amp;publication_year=2014&amp;journal=Cell+Mol+Immunol&amp;pages=141-149&amp;doi=10.1038%2Fcmi.2013.61&amp;pmid=24509444" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Wathelet MG, Orr M, Frieman MB, Baric RS. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. <em>J Virol</em> 2007;81:11620-11633.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JVI.00702-07" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17715225/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000250417400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Severe+acute+respiratory+syndrome+coronavirus+evades+antiviral+signaling%3A+role+of+nsp1+and+rational+design+of+an+attenuated+strain.&amp;publication_year=2007&amp;journal=J+Virol&amp;pages=11620-11633&amp;doi=10.1128%2FJVI.00702-07&amp;pmid=17715225" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Lee JY, Bae S, Myoung J. Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design. <em>J Microbiol</em> 2019;57:803-811.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12275-019-9272-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31452044/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000482929400010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Middle+East+respiratory+syndrome+coronavirus-encoded+ORF8b+strongly+antagonizes+IFN-%CE%B2+promoter+activation%3A+its+implication+for+vaccine+design.&amp;publication_year=2019&amp;journal=J+Microbiol&amp;pages=803-811&amp;doi=10.1007%2Fs12275-019-9272-7&amp;pmid=31452044" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Yang Y, Ye F, Zhu N, et al. Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets. <em>Sci Rep</em> 2015;5:17554-17554.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/srep17554" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26631542/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365690100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Middle+East+respiratory+syndrome+coronavirus+ORF4b+protein+inhibits+type+I+interferon+production+through+both+cytoplasmic+and+nuclear+targets.&amp;publication_year=2015&amp;journal=Sci+Rep&amp;pages=17554-17554&amp;doi=10.1038%2Fsrep17554&amp;pmid=26631542" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. <em>Cell</em> 2020;181:1036-1045.e9.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2020.04.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32416070/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000537399500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Imbalanced+host+response+to+SARS-CoV-2+drives+development+of+COVID-19.&amp;publication_year=2020&amp;journal=Cell&amp;pages=1036-1045.e9&amp;doi=10.1016%2Fj.cell.2020.04.026&amp;pmid=32416070" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. <em>Science</em> 2020;369:718-724.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abc6027" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32661059/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559184400051" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impaired+type+I+interferon+activity+and+inflammatory+responses+in+severe+COVID-19+patients.&amp;publication_year=2020&amp;journal=Science&amp;pages=718-724&amp;doi=10.1126%2Fscience.abc6027&amp;pmid=32661059" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <em>Science</em> 2020 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd4570" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32972995/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077200034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inborn+errors+of+type+I+IFN+immunity+in+patients+with+life-threatening+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;doi=10.1126%2Fscience.abd4570&amp;pmid=32972995" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="r39" class="citations"><div class="citation"><div class="citation-content">Bastard P, Rosen LB, Zhang Q, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. <em>Science</em> 2020 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd4585" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32972996/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077200035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Auto-antibodies+against+type+I+IFNs+in+patients+with+life-threatening+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;doi=10.1126%2Fscience.abd4585&amp;pmid=32972996" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="r40" class="citations"><div class="citation"><div class="citation-content">Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. <em>Lancet</em> 2020;395:1695-1704.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r40" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)31042-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32401715/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561610000023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple+combination+of+interferon+beta-1b%2C+lopinavir-ritonavir%2C+and+ribavirin+in+the+treatment+of+patients+admitted+to+hospital+with+COVID-19%3A+an+open-label%2C+randomised%2C+phase+2+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1695-1704&amp;doi=10.1016%2FS0140-6736%2820%2931042-4&amp;pmid=32401715" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r40" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r40-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] treatment with lopinavir–ritonavir alone. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r42" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] concerns about its proinflammatory effects. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">41.</div><div id="r41" class="citations"><div class="citation"><div class="citation-content">Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV–infected mice. <em>Cell Host Microbe</em> 2016;19:181-193.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.chom.2016.01.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26867177/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000369840100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dysregulated+type+I+interferon+and+inflammatory+monocyte-macrophage+responses+cause+lethal+pneumonia+in+SARS-CoV%E2%80%93infected+mice.&amp;publication_year=2016&amp;journal=Cell+Host+Microbe&amp;pages=181-193&amp;doi=10.1016%2Fj.chom.2016.01.007&amp;pmid=26867177" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">42.</div><div id="r42" class="citations"><div class="citation"><div class="citation-content">Channappanavar R, Fehr AR, Zheng J, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. <em>J Clin Invest</em> 2019;129:3625-3639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI126363" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31355779/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000484368600022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IFN-I+response+timing+relative+to+virus+replication+determines+MERS+coronavirus+infection+outcomes.&amp;publication_year=2019&amp;journal=J+Clin+Invest&amp;pages=3625-3639&amp;doi=10.1172%2FJCI126363&amp;pmid=31355779" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">43.</div><div id="r43" class="citations"><div class="citation"><div class="citation-content">Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. <em>Int Immunopharmacol</em> 2020 August 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r44"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.intimp.2020.106903" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32862111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000588166300127" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interferon+%CE%B2-1b+in+treatment+of+severe+COVID-19%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=Int+Immunopharmacol&amp;doi=10.1016%2Fj.intimp.2020.106903&amp;pmid=32862111" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">44.</div><div id="r44" class="citations"><div class="citation"><div class="citation-content">Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe Covid-19. <em>Antimicrob Agents Chemother</em> 2020;64(9):e01061-20-e01061-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r44"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.01061-20" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32661006/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000680923300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized+clinical+trial+of+the+efficacy+and+safety+of+interferon+%CE%B2-1a+in+treatment+of+severe+Covid-19.&amp;publication_year=2020&amp;journal=Antimicrob+Agents+Chemother&amp;pages=e01061-20-e01061-20&amp;doi=10.1128%2FAAC.01061-20&amp;pmid=32661006" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">45.</div><div id="r45" class="citations"><div class="citation"><div class="citation-content">Synairgen. Synairgen announces positive results from trial of SNG001 in hospitalised Covid-19 patients. July 20, 2020 (<a href="https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf">https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Synairgen.+Synairgen+announces+positive+results+from+trial+of+SNG001+in+hospitalised+Covid-19+patients.+July+20%2C+2020+%28https%3A%2F%2Fwww.synairgen.com%2Fwp-content%2Fuploads%2F2020%2F07%2F200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">46.</div><div id="r46" class="citations"><div class="citation"><div class="citation-content">Bellingan G, Maksimow M, Howell DC, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. <em>Lancet Respir Med</em> 2014;2:98-107.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r46" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(13)70259-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24503265/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000333768500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+effect+of+intravenous+interferon-beta-1a+%28FP-1201%29+on+lung+CD73+expression+and+on+acute+respiratory+distress+syndrome+mortality%3A+an+open-label+study.&amp;publication_year=2014&amp;journal=Lancet+Respir+Med&amp;pages=98-107&amp;doi=10.1016%2FS2213-2600%2813%2970259-5&amp;pmid=24503265" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r46" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r48-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with moderate-to-severe ARDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r46-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] lower 28-day mortality than use of placebo. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">47.</div><div id="r47" class="citations"><div class="citation"><div class="citation-content">Ranieri VM, Pettilä V, Karvonen MK, et al. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. <em>JAMA</em> 2020;323:725-733.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r47" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2019.22525" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32065831/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000518617500022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+intravenous+interferon+%CE%B2-1a+on+death+and+days+free+from+mechanical+ventilation+among+patients+with+moderate+to+severe+acute+respiratory+distress+syndrome%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=725-733&amp;doi=10.1001%2Fjama.2019.22525&amp;pmid=32065831" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r47" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r48-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with moderate-to-severe ARDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r47-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] number of ventilator-free days at day 28). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r48-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] beta-1a without glucocorticoids was not. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">48.</div><div id="r48" class="citations"><div class="citation"><div class="citation-content">Shankar-Hari M, Calfee CS. Lack of clinical benefit of interferon β-1a among patients with severe acute respiratory distress syndrome: time to overhaul drug trials in ARDS? <em>JAMA</em> 2020 February 17 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r48" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2019.22524" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32065830/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000518617500018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lack+of+clinical+benefit+of+interferon+%CE%B2-1a+among+patients+with+severe+acute+respiratory+distress+syndrome%3A+time+to+overhaul+drug+trials+in+ARDS%3F&amp;publication_year=2020&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2019.22524&amp;pmid=32065830" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r48" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r48-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with moderate-to-severe ARDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r48-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] beta-1a without glucocorticoids was not. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">49.</div><div id="r49" class="citations"><div class="citation"><div class="citation-content">Jalkanen J, Pettilä V, Huttunen T, Hollmén M, Jalkanen S. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. <em>Intensive Care Med</em> 2020 May 19 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r49"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00134-020-06086-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32430515/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534200300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glucocorticoids+inhibit+type+I+IFN+beta+signaling+and+the+upregulation+of+CD73+in+human+lung.&amp;publication_year=2020&amp;journal=Intensive+Care+Med&amp;doi=10.1007%2Fs00134-020-06086-3&amp;pmid=32430515" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">50.</div><div id="r50" class="citations"><div class="citation"><div class="citation-content">Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. <em>N Engl J Med</em>.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r50"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_6_51_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2015294&amp;key=10.1056%2FNEJMoa2021436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000623807600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dexamethasone+in+hospitalized+patients+with+Covid-19+%E2%80%94+preliminary+report.&amp;journal=N+Engl+J+Med&amp;doi=10.1056%2FNEJMoa2021436" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">51.</div><div id="r51" class="citations"><div class="citation"><div class="citation-content">Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. <em>Nature</em> 2020;585:273-276.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r51"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-020-2423-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32516797/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000565516300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+benefit+of+remdesivir+in+rhesus+macaques+infected+with+SARS-CoV-2.&amp;publication_year=2020&amp;journal=Nature&amp;pages=273-276&amp;doi=10.1038%2Fs41586-020-2423-5&amp;pmid=32516797" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/17"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">17</span></span> • <span property="datePublished">October 22, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1645</span>-<span property="pageEnd">1656</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2015294" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2015294?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: October 7, 2020</div><div><b class="core-label">Published in issue</b>: October 22, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pulmonary-critical-care-general" alt="View article keyword Pulmonary/Critical Care General" data-interactiontype="article_recirculation_click">Pulmonary/Critical Care General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/viral-infections" alt="View article keyword Viral Infections" data-interactiontype="article_recirculation_click">Viral Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Yaseen M.</span> <span property="familyName">Arabi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ayed Y.</span> <span property="familyName">Asiri</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Abdullah M.</span> <span property="familyName">Assiri</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hanan H.</span> <span property="familyName">Balkhy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ali</span> <span property="familyName">Al Bshabshe</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Majed</span> <span property="familyName">Al Jeraisy</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yasser</span> <span property="familyName">Mandourah</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mohamed H.A.</span> <span property="familyName">Azzam</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Abdulhadi M.</span> <span property="familyName">Bin Eshaq</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7873-1159" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7873-1159</a></span>, <span property="author" typeof="Person"><span property="givenName">Sameera</span> <span property="familyName">Al Johani</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shmeylan</span> <span property="familyName">Al Harbi</span>, <span property="honorificSuffix">Pharm.D., B.C.P.S</span></span>, <span property="author" typeof="Person"><span property="givenName">Hani A.A.</span> <span property="familyName">Jokhdar</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ahmad M.</span> <span property="familyName">Deeb</span>, <span property="honorificSuffix">R.N., M.S.N.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-3680-7338" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-3680-7338</a></span>, <span property="author" typeof="Person"><span property="givenName">Ziad A.</span> <span property="familyName">Memish</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jesna</span> <span property="familyName">Jose</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sameeh</span> <span property="familyName">Ghazal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sarah</span> <span property="familyName">Al Faraj</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ghaleb A.</span> <span property="familyName">Al Mekhlafi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nisreen M.</span> <span property="familyName">Sherbeeni</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fatehi E.</span> <span property="familyName">Elzein</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fahad</span> <span property="familyName">Al-Hameed</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Asim</span> <span property="familyName">Al Saedi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Naif K.</span> <span property="familyName">Alharbi</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert A.</span> <span property="familyName">Fowler</span>, <span property="honorificSuffix">M.D.C.M.</span></span>, <span property="author" typeof="Person"><span property="givenName">Frederick G.</span> <span property="familyName">Hayden</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Abdulaziz</span> <span property="familyName">Al-Dawood</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mohamed</span> <span property="familyName">Abdelzaher</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wail</span> <span property="familyName">Bajhmom</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Badriah M.</span> <span property="familyName">AlMutairi</span>, <span property="honorificSuffix">R.N.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mohamed A.</span> <span property="familyName">Hussein</span>, <span property="honorificSuffix">M.S.C.S., M.S.P.H., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Adel</span> <span property="familyName">Alothman</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the Saudi Critical Care Trials Group<sup><a href="#fn2" role="doc-noteref">†</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Intensive Care Department (Y.M.A., A.A.-D.) and the Departments of Infection Prevention and Control (H.H.B.), Pathology and Laboratory Medicine (S.A.J.), Pharmaceutical Care (S.A.H.), and Medicine (A.A.), King Abdulaziz Medical City, Ministry of National Guard Health Affairs, the College of Medicine (Y.M.A., S.A.J., A.A.-D., A.A.) and the College of Pharmacy (M.A.J., S.A.H.), King Saud bin Abdulaziz University for Health Sciences, Prince Mohammed bin Abdulaziz Hospital (A.Y.A., Z.A.M., S.G., S.A.F.), Infection Prevention and Control, Preventive Health (A.M.A.), and Deputyship for Public Health (H.A.A.J.), Ministry of Health, Clinical Trials Services (M.A.J., A.M.D., B.M.A.) and the Departments of Biostatistics and Informatics (J.J., M.A.H.) and Infectious Disease Research (N.K.A.), King Abdullah International Medical Research Center, the Military Medical Services, Ministry of Defense (Y.M.), the Department of Intensive Care Services (G.A.A.M.), and the Infectious Diseases Division (N.M.S., F.E.E.), Prince Sultan Military Medical City, and the College of Medicine, Alfaisal University (Z.A.M.), Riyadh, the Department of Critical Care Medicine, King Khalid University, Aseer Central Hospital, Abha (A.A.B.), Medical Services (M.H.A.A.) and the Department of Critical Care Medicine (M.A.), King Abdullah Medical Complex, the Health Directorate, Ministry of Health (M.H.A.A.), and the Internal Medicine Department, King Fahad General Hospital, Ministry of Health (W.B.), the Intensive Care Department (F.A.-H.) and the Department of Infection Prevention and Control (A.A.S.), Ministry of National Guard Health Affairs, and the College of Medicine and King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center (F.A.-H., A.A.S.), Jeddah, and the Intensive Care Department, King Khalid Hospital, Najran (A.M.B.E.) — all in Saudi Arabia; the World Health Organization, Geneva (H.H.B.); the Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta (Z.A.M.); the Departments of Critical Care Medicine and Medicine, Sunnybrook Hospital, and the Institute of Health Policy Management and Evaluation, University of Toronto, Toronto (R.A.F.); and the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Arabi at P.O. Box 22490, Riyadh 11426, Saudi Arabia, or at <a href="mailto:arabi@ngha.med.sa">arabi@ngha.med.sa</a>.</div><div role="doc-footnote"><div id="fn1" role="paragraph">Adel Alothman, M.D., is deceased.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="fn2" role="paragraph">A full list of the members of the Saudi Critical Care Trials Group is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">63</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2015294" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="51e9dd9e-fae1-ac8a-15df-54375023ece0"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91934253" style="display:inline-block;">
                <img alt="Article has an altmetric score of 356" src="https://badges.altmetric.com/?size=320&amp;score=356&amp;types=mbttttfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91934253">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_51e9dd9e-fae1-ac8a-15df-54375023ece0" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91934253&amp;tab=news">
          Picked up by <b>10</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91934253&amp;tab=blogs">
          Blogged by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91934253&amp;tab=policy-documents">
          Referenced in <b>2</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91934253&amp;tab=twitter">
          Posted by <b>359</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91934253&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>191</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6515ae59fa3fc-GRU"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2015294"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2015294%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-17%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="63" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Donald C. Vinh, </li></ul><span class="cited-by__entry__title">Host-directed immunotherapy for viral infections, </span><span class="cited-by__entry__series-title">Current Opinion in Infectious Diseases, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/QCO.0000000000001116" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/QCO.0000000000001116</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/QCO.0000000000001116" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Janet A. Englund, </li><li class="list-inline-item cited-by__entry__author">Yae-Jean Kim, </li><li class="list-inline-item cited-by__entry__author">Kenneth McIntosh, </li><li class="list-inline-item cited-by__entry__author">Annabelle de St. Maurice, </li><li class="list-inline-item cited-by__entry__author">Megan Culler Freeman, </li><li class="list-inline-item cited-by__entry__author">Mark R. Denison, </li></ul><span class="cited-by__entry__title">Human Coronaviruses, </span><span class="cited-by__entry__series-title">Feigin and Cherry's Textbook of Pediatric Infectious Diseases, </span><span class="cited-by__entry__page-range">(1934-1946.e6), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/B978-0-323-82763-8.00201-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/B978-0-323-82763-8.00201-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/B978-0-323-82763-8.00201-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jaffar A. Al-Tawfiq, </li></ul><span class="cited-by__entry__title">Developments in treatment for middle east respiratory syndrome coronavirus (MERS-CoV), </span><span class="cited-by__entry__series-title">Expert Review of Respiratory Medicine, </span><span class="cited-by__entry__volume"><strong>18</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(295-307), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1080/17476348.2024.2369714" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/17476348.2024.2369714</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/17476348.2024.2369714" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Feifei Qi, </li><li class="list-inline-item cited-by__entry__author">Yiwei Yan, </li><li class="list-inline-item cited-by__entry__author">Qi Lv, </li><li class="list-inline-item cited-by__entry__author">Mingya Liu, </li><li class="list-inline-item cited-by__entry__author">Ming Liu, </li><li class="list-inline-item cited-by__entry__author">Fengdi Li, </li><li class="list-inline-item cited-by__entry__author">Ran Deng, </li><li class="list-inline-item cited-by__entry__author">Xujian Liang, </li><li class="list-inline-item cited-by__entry__author">Shuyue Li, </li><li class="list-inline-item cited-by__entry__author">Guocui Mou, </li><li class="list-inline-item cited-by__entry__author">Linlin Bao, </li></ul><span class="cited-by__entry__title">
                  IL
              ‐37 possesses both anti‐inflammatory and antiviral effects against Middle East respiratory syndrome coronavirus infection
            , </span><span class="cited-by__entry__series-title">Animal Models and Experimental Medicine, </span><span class="cited-by__entry__volume"><strong>8</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(483-492), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1002/ame2.12435" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/ame2.12435</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/ame2.12435" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jaffar A. Al-Tawfiq, </li><li class="list-inline-item cited-by__entry__author">Ziad A. Memish, </li></ul><span class="cited-by__entry__title">Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Travellers, </span><span class="cited-by__entry__series-title">Emerging and Re-emerging Infections in Travellers, </span><span class="cited-by__entry__page-range">(311-329), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1007/978-3-031-49475-8_20" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/978-3-031-49475-8_20</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/978-3-031-49475-8_20" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Elise G. Viox, </li><li class="list-inline-item cited-by__entry__author">Steven E. Bosinger, </li><li class="list-inline-item cited-by__entry__author">Daniel C. Douek, </li><li class="list-inline-item cited-by__entry__author">Gideon Schreiber, </li><li class="list-inline-item cited-by__entry__author">Mirko Paiardini, </li></ul><span class="cited-by__entry__title">Harnessing the power of IFN for therapeutic approaches to COVID-19, </span><span class="cited-by__entry__series-title">Journal of Virology, </span><span class="cited-by__entry__volume"><strong>98</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1128/jvi.01204-23" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1128/jvi.01204-23</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1128/jvi.01204-23" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jasper Fuk-Woo Chan, </li><li class="list-inline-item cited-by__entry__author">Shuofeng Yuan, </li><li class="list-inline-item cited-by__entry__author">Hin Chu, </li><li class="list-inline-item cited-by__entry__author">Siddharth Sridhar, </li><li class="list-inline-item cited-by__entry__author">Kwok-Yung Yuen, </li></ul><span class="cited-by__entry__title">COVID-19 drug discovery and treatment options, </span><span class="cited-by__entry__series-title">Nature Reviews Microbiology, </span><span class="cited-by__entry__volume"><strong>22</strong>, </span><span class="cited-by__entry__issue">7, </span><span class="cited-by__entry__page-range">(391-407), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1038/s41579-024-01036-y" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41579-024-01036-y</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41579-024-01036-y" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Arnold S. Monto, </li><li class="list-inline-item cited-by__entry__author">Benjamin J. Cowling, </li><li class="list-inline-item cited-by__entry__author">Joseph Sriyal Malik Peiris, </li></ul><span class="cited-by__entry__title">Coronaviruses: The Common Cold, SARS, and MERS, </span><span class="cited-by__entry__series-title">Viral Infections of Humans, </span><span class="cited-by__entry__page-range">(1-53), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1007/978-1-4939-9544-8_67-1" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/978-1-4939-9544-8_67-1</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/978-1-4939-9544-8_67-1" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Qiaoshuai Lan, </li><li class="list-inline-item cited-by__entry__author">Yan Yan, </li><li class="list-inline-item cited-by__entry__author">Guangxu Zhang, </li><li class="list-inline-item cited-by__entry__author">Shuai Xia, </li><li class="list-inline-item cited-by__entry__author">Jie Zhou, </li><li class="list-inline-item cited-by__entry__author">Lu Lu, </li><li class="list-inline-item cited-by__entry__author">Shibo Jiang, </li></ul><span class="cited-by__entry__title">Clinical development of antivirals against SARS-CoV-2 and its variants, </span><span class="cited-by__entry__series-title">Current Research in Microbial Sciences, </span><span class="cited-by__entry__volume"><strong>6</strong>, </span><span class="cited-by__entry__page-range">(100208), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.crmicr.2023.100208" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.crmicr.2023.100208</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.crmicr.2023.100208" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yaseen M. Arabi, </li><li class="list-inline-item cited-by__entry__author">Hasan M. Al-Dorzi, </li><li class="list-inline-item cited-by__entry__author">Samah AlQahtani, </li><li class="list-inline-item cited-by__entry__author">Zohair Al Aseri, </li><li class="list-inline-item cited-by__entry__author">Sara Aldekhyl, </li><li class="list-inline-item cited-by__entry__author">Zainab Al Duhailib, </li><li class="list-inline-item cited-by__entry__author">Farhan Alenezi, </li><li class="list-inline-item cited-by__entry__author">Haifa Algethamy, </li><li class="list-inline-item cited-by__entry__author">Waleed Alhazzani, </li><li class="list-inline-item cited-by__entry__author">Haifaa Ibrahim Alhumedi, </li><li class="list-inline-item cited-by__entry__author">Yasser Mohammed Kazzaz, </li><li class="list-inline-item cited-by__entry__author">Mohammed S. Alshahrani, </li><li class="list-inline-item cited-by__entry__author">Marwa Amer, </li><li class="list-inline-item cited-by__entry__author">Ahmed Algahtani, </li><li class="list-inline-item cited-by__entry__author">Wadiah Alawi M. Al-Filfil, </li></ul><span class="cited-by__entry__title">Critical Care Research in Saudi Arabia: Onward and Upward, </span><span class="cited-by__entry__series-title">Saudi Critical Care Journal, </span><span class="cited-by__entry__volume"><strong>7</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(49-52), </span><span class="cited-by__entry__pub-date">(2023).</span><a href="https://doi.org/10.4103/sccj.sccj_18_23" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.4103/sccj.sccj_18_23</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.4103/sccj.sccj_18_23" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2015294%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-17%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2015294" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2015294" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2015294.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2015294_f1.jpg"><img src="/cms/10.1056/NEJMoa2015294/asset/fdebc372-176d-4a6d-a967-d5590567d359/assets/images/large/nejmoa2015294_f1.jpg" height="2700" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Probability of Survival and Subgroup Analyses.</div><div class="notes"><div role="doc-footnote">Panel A shows a Kaplan–Meier survival analysis involving all the patients enrolled in the trial. Panel B shows the results of prespecified subgroup analyses of the primary outcome (90-day all-cause mortality). Two-sided P values for interaction are reported. The false discovery rate (FDR) accounts for multiplicity by calculating the expected proportion of tests with false positives at a specified rank of a set of tests. The size of each square is proportional to the subgroup sample size. Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores indicating more severe disease and a higher risk of death.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2015294_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2015294/asset/ad0934e8-b6dc-4f30-ab6f-54fb8bea72c0/assets/images/large/nejmoa2015294_t1.jpg" height="2912" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Intervention Group<br>(N=43)</th><th class="txxr-borders">Placebo Group<br>(N=52)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">56 (43–67)</td><td class="xxxr-borders shading">56 (43.5–67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">31 (72)</td><td class="xxxr-borders">44 (85)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Body-mass index</td><td class="xxxx-borders shading">28.3±5.5</td><td class="xxxr-borders shading">27.2±5.7</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Acquisition of MERS — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Community-acquired acquisition</td><td class="xxxx-borders shading">28 (65)</td><td class="xxxr-borders shading">38 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nosocomial acquisition</td><td class="xxxx-borders">15 (35)</td><td class="xxxr-borders">14 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Coinfection with any other virus or bacterium — no. (%)</td><td class="xxxx-borders shading">6 (14)</td><td class="xxxr-borders shading">7 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">APACHE II score<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">19.1±10.4</td><td class="xxxr-borders">20.4±11.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median SOFA score (IQR)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">6 (3–9)</td><td class="xxxr-borders shading">6 (3–9.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median Karnofsky performance-status score (IQR)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">90 (70–100)</td><td class="xxxr-borders">100 (80–100)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Coexisting conditions — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any chronic coexisting condition</td><td class="xxxx-borders">38 (88)</td><td class="xxxr-borders">45 (87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Chronic cardiac disease</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxr-borders shading">13 (25)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Chronic pulmonary disease</td><td class="xxxx-borders">3 (7)</td><td class="xxxr-borders">2 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Chronic renal disease</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxr-borders shading">15 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diabetes with chronic complications</td><td class="xxxx-borders">18 (42)</td><td class="xxxr-borders">17 (33)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Location at time of randomization — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Ward</td><td class="xxxx-borders">14 (33)</td><td class="xxxr-borders">13 (25)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">ICU</td><td class="xxxx-borders shading">29 (67)</td><td class="xxxr-borders shading">39 (75)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Randomization stratum — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mechanical ventilation</td><td class="xxxx-borders shading">18 (42)</td><td class="xxxr-borders shading">21 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No mechanical ventilation</td><td class="xxxx-borders">25 (58)</td><td class="xxxr-borders">31 (60)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Interventions before randomization — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Renal-replacement therapy</td><td class="xxxx-borders">10 (23)</td><td class="xxxr-borders">14 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Vasopressor therapy</td><td class="xxxx-borders shading">8 (19)</td><td class="xxxr-borders shading">12 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neuromuscular blockade</td><td class="xxxx-borders">11 (26)</td><td class="xxxr-borders">15 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glucocorticoids</td><td class="xxxx-borders shading">15 (35)</td><td class="xxxr-borders shading">15 (29)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Laboratory results before randomization — median (IQR)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Platelet count per mm<sup>3</sup></td><td class="xxxx-borders shading">181,000<br>(145,000–254,000)</td><td class="xxxr-borders shading">182,500<br>(154,000–235,000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White-cell count per mm<sup>3</sup></td><td class="xxxx-borders">6300 (5000–9000)</td><td class="xxxr-borders">6900 (4100–8900)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Lymphocyte count per mm<sup>3</sup></td><td class="xxxx-borders shading">1000 (500–1300)</td><td class="xxxr-borders shading">800 (600–1200)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Aspartate aminotransferase — U/liter</td><td class="xxxx-borders">55 (33–79)</td><td class="xxxr-borders">78 (45–114)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Alanine aminotransferase — U/liter</td><td class="xxxx-borders shading">42 (29–62)</td><td class="xxxr-borders shading">46 (22–76)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bilirubin — μmol/liter</td><td class="xxxx-borders">9 (6–12)</td><td class="xxxr-borders">9 (6–16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Creatinine — μmol/liter</td><td class="xbxx-borders shading">79 (64–202)</td><td class="xbxr-borders shading">94 (68–315)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Patients in the intervention group received recombinant interferon beta-1b and lopinavir–ritonavir. Continuous variables were compared between the two trial groups with the use of an independent Student’s t-test or Mann–Whitney test, and categorical variables were compared with the use of a chi-square test or Fisher’s exact test. None of the baseline characteristics differed significantly between the two trial groups. Data on the following characteristics were missing as follows: on the body-mass index (the weight in kilograms divided by the square of the height in meters), for one patient in the placebo group; on the lymphocyte count, for five patients in the intervention group and three in the placebo group; on the aspartate aminotransferase level, for two and one, respectively; on the alanine aminotransferase level for one and one, respectively; and on the bilirubin level, for one in the placebo group. To convert the values for bilirubin to milligrams per deciliter, divide by 17.1. To convert the values for creatinine to milligrams per deciliter, divide by 88.4. Additional details on the baseline characteristics are provided in Table S6. ICU denotes intensive care unit, IQR interquartile range, and MERS Middle East respiratory syndrome.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores indicating more severe disease and a higher risk of death.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Scores on the Sequential Organ Failure Assessment (SOFA) range from 0 to 24, with higher scores indicating a greater degree of organ dysfunction.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Karnofsky performance-status scores range from 0 (death) to 100 (normal performance status).</div></div></div></figcaption></a><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2015294/asset/67dd325a-8d46-437a-954c-72e2e49ce726/assets/images/large/nejmoa2015294_t2.jpg" height="1404" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Intervention Group<br>(N=43)</th><th class="txxr-borders">Placebo Group<br>(N=52)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Interventions — median (IQR)</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">No. of interferon beta-1b or placebo injection doses</td><td class="xxxx-borders">7 (5–7)</td><td class="xxxr-borders">7 (4–7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">No. of lopinavir–ritonavir or placebo doses</td><td class="xxxx-borders shading">27 (14–28)</td><td class="xxxr-borders shading">26 (12.5–28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Time from onset of symptoms to randomization — days</td><td class="xxxx-borders">7 (5–11)</td><td class="xxxr-borders">7.5 (5–10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Time from admission to randomization — days</td><td class="xxxx-borders shading">2 (1–4)</td><td class="xxxr-borders shading">1 (1–3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Time from randomization to receipt of the first dose — days</td><td class="xxxx-borders">0 (0–0)</td><td class="xxxr-borders">0 (0–0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Time from the first positive RT-PCR assay to receipt of the first dose — days</td><td class="xxxx-borders shading">1 (0–3)</td><td class="xxxr-borders shading">1 (1–2.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Cointerventions</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Vasopressor therapy — no. (%)</td><td class="xxxx-borders shading">21 (49)</td><td class="xxxr-borders shading">30 (58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Renal-replacement therapy — no. (%)</td><td class="xxxx-borders">19 (44)</td><td class="xxxr-borders">24 (46)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Neuromuscular blockade — no. (%)</td><td class="xxxx-borders shading">22 (51)</td><td class="xxxr-borders shading">28 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Invasive mechanical ventilation — no. (%)</td><td class="xxxx-borders">26 (60)</td><td class="xxxr-borders">35 (67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Noninvasive mechanical ventilation — no. (%)</td><td class="xxxx-borders shading">4 (9)</td><td class="xxxr-borders shading">9 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Extracorporeal membrane oxygenation — no. (%)</td><td class="xxxx-borders">6 (14)</td><td class="xxxr-borders">5 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Glucocorticoids — no. (%)</td><td class="xxxx-borders shading">27 (63)</td><td class="xxxr-borders shading">31 (60)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Median duration of glucocorticoid therapy (IQR) — days<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xbxx-borders">8 (6–13)</td><td class="xbxr-borders">9 (4–18)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Continuous variables were compared between the two trial groups with the use of an independent Student’s t-test or Mann–Whitney test, and categorical variables were compared with the use of a chi-square test or Fisher’s exact test. None of the variables differed significantly between the two trial groups. Additional details on interventions and cointerventions are provided in Table S8. RT-PCR denotes reverse transcriptase–polymerase chain reaction.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The analysis of duration of glucocorticoid therapy included only patients who received a glucocorticoid.</div></div></div></figcaption></a><figcaption><div class="caption">Interventions and Cointerventions during the Trial Period.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2015294/asset/48a45c82-06cb-4cbe-b82c-89f636a11a1c/assets/images/large/nejmoa2015294_t3.jpg" height="917" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Intervention<br>Group<br>(N=43)</th><th class="txxx-borders">Placebo<br>Group<br>(N=52)</th><th class="txxx-borders">Risk Difference<br>(Upper Boundary of 97.5% CI)</th><th class="txxr-borders">One-Sided<br>P Value</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">percentage points</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Death by day 90 — no. (%)</td><td class="xxxx-borders shading">12 (28)</td><td class="xxxx-borders shading">23 (44)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Primary analysis: 90-day mortality — %<a href="#core-t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">29</td><td class="xxxx-borders">48</td><td class="xxxx-borders">−19 (−3)</td><td class="xxxr-borders">0.024</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Crude analysis: 90-day mortality — %<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xbxx-borders shading">28</td><td class="xbxx-borders shading">44</td><td class="xbxx-borders shading">−16 (3)</td><td class="xbxr-borders shading">0.05</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t3.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t3.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The primary analysis accounted for the adaptive design of the trial according to the published statistical analysis plan. Mortality at 90 days in each trial group was a combined estimate of the observed 90-day mortality from the first and second interim analyses, weighted by the inverse variance of each estimate. The risk difference was calculated as the difference in 90-day mortality between the intervention group and the placebo group. The upper boundary of the 97.5% confidence interval was calculated. A one-sided P value was calculated with the use of the Z test for difference in proportion. A one-sided P value of 0.025 or less was considered to indicate statistical significance.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t3.jpg"><div class="label">†</div></a><div id="core-t3fn2" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t3.jpg">A crude analysis was conducted, for illustration purposes, with the use of a Z test. The reported one-sided P value does not account for the planned stage-wise approach or for the error spending and conditional error principle used in the design of the trial, which provide more gain in power than the traditional crude approach.<sup></sup></a><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="core-body-ref-r19-3" href-manipulated="true" aria-label="Reference 19" data-to-manipulate="false">19</a> Results of multivariate analyses are reported in Table S12.</div></div></div></figcaption><figcaption><div class="caption">90-Day All-Cause Mortality (Primary Outcome).</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t4"><figure class="table"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t4.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2015294/asset/4d769501-f8de-4aaf-879e-af027e03941d/assets/images/large/nejmoa2015294_t4.jpg" height="2323" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Intervention Group<br>(N=43)</th><th class="txxx-borders">Placebo Group<br>(N=52)</th><th class="txxr-borders">Relative Risk<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Death from any cause — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">By day 28</td><td class="xxxx-borders">10 (23)</td><td class="xxxx-borders">17 (33)</td><td class="xxxr-borders">0.71 (0.36–1.39)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">During ICU stay</td><td class="xxxx-borders shading">12 (28)</td><td class="xxxx-borders shading">22 (42)</td><td class="xxxr-borders shading">0.66 (0.37–1.17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">During hospital stay</td><td class="xxxx-borders">13 (30)<a href="#core-t4fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">23 (44)</td><td class="xxxr-borders">0.68 (0.40–1.18)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Alive at day 90 — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Receiving renal-replacement therapy</td><td class="xxxx-borders">6 (14)</td><td class="xxxx-borders">3 (6)</td><td class="xxxr-borders">2.42 (0.64–9.11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Receiving supplemental oxygen</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxr-borders shading">3.63 (0.39–33.63)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Receiving invasive mechanical ventilation</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (2)</td><td class="xxxr-borders">2.42 (0.23–25.78)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Median duration (IQR) — days<a href="#core-t4fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Free from supplemental oxygen therapy</td><td class="xxxx-borders">4 (0–19)</td><td class="xxxx-borders">0 (0–17)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Free from invasive or noninvasive mechanical ventilation</td><td class="xxxx-borders shading">16 (0–28)</td><td class="xxxx-borders shading">5.5 (0–28)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Free from renal-replacement therapy</td><td class="xxxx-borders">28 (7–28)</td><td class="xxxx-borders">22 (0–28)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Free from vasopressor therapy</td><td class="xxxx-borders shading">27 (3–28)</td><td class="xxxx-borders shading">24.5 (0–28)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Free from extracorporeal membrane oxygenation</td><td class="xxxx-borders">28 (0–28)</td><td class="xxxx-borders">28 (0–28)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Free from organ support</td><td class="xxxx-borders shading">15 (0–28)</td><td class="xxxx-borders shading">5 (0–27.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Outside the ICU</td><td class="xxxx-borders">9 (0–28)</td><td class="xxxx-borders">0 (0–18)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Of hospital stay</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Among all patients</td><td class="xxxx-borders">22 (11–40)</td><td class="xxxx-borders">17.5 (8–34)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Among patients surviving to 90 days</td><td class="xxxx-borders shading">26 (14–43)</td><td class="xxxx-borders shading">20 (10–37)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Virologic outcomes</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Median no. of days to MERS-CoV RNA clearance (IQR)<a href="#core-t4fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Among all patients</td><td class="xxxx-borders">17 (9–25)</td><td class="xxxx-borders">20 (10–33)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Among patients surviving to 90 days</td><td class="xxxx-borders shading">13 (8–21)</td><td class="xxxx-borders shading">12 (9–22)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Functional outcome</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median Karnofsky performance-status score at day 90 (IQR)<a href="#core-t4fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">70 (0–100)</td><td class="xxxx-borders shading">50 (0–100)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Safety outcomes</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Serious adverse event — no. (%)<a href="#core-t4fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">4 (9)</td><td class="xxxx-borders shading">10 (19)</td><td class="xxxr-borders shading">0.48 (0.16–1.43)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Acute pancreatitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (2)</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Elevation of alanine aminotransferase level to &gt;5× ULN</td><td class="xxxx-borders shading">4 (9)</td><td class="xxxx-borders shading">9 (17)</td><td class="xxxr-borders shading">0.54 (0.18–1.62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">Other serious adverse event</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (2)</td><td class="xbxr-borders">—</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t4fn1" role="paragraph" data-to-manipulate="true">The 95% confidence intervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproducible. MERS-CoV denotes MERS coronavirus, and ULN upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t4fn2" role="paragraph" data-to-manipulate="true">One patient in the intervention group died during the hospital stay after day 90.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t4fn3" role="paragraph" data-to-manipulate="true">The calculations of days free from supplemental oxygen therapy, days free from mechanical ventilation, days free from renal-replacement therapy, days free from vasopressor therapy, days free from extracorporeal membrane oxygenation, days free from organ support, and days outside the ICU were based on 28 days of observation.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t4fn4" role="paragraph" data-to-manipulate="true">Days to clearance of MERS-CoV RNA were censored by death or hospital discharge.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t4fn5" role="paragraph" data-to-manipulate="true">Data on the Karnofsky performance-status score at day 90 were not available for one patient in the placebo group.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t4fn6" role="paragraph" data-to-manipulate="true">P values for serious adverse events are provided in Table S10.</div></div></div></figcaption></a><figcaption><div class="caption">Secondary Outcomes.<a href="#core-t4fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t4"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2015294_t4.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2015294</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). 2019 (<a href="https://www.who.int/emergencies/mers-cov/en/">https://www.who.int/emergencies/mers-cov/en/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=World+Health+Organization.+Middle+East+respiratory+syndrome+coronavirus+%28MERS-CoV%29.+2019+%28https%3A%2F%2Fwww.who.int%2Femergencies%2Fmers-cov%2Fen%2F%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. <em>N Engl J Med</em> 2017;376:584-594.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_6_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2015294&amp;key=10.1056%2FNEJMsr1408795&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28177862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393510500018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Middle+East+respiratory+syndrome.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=584-594&amp;doi=10.1056%2FNEJMsr1408795&amp;pmid=28177862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Al-Omari A, Mandourah Y, et al. Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. <em>Crit Care Med</em> 2017;45:1683-1695.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCM.0000000000002621" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28787295/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410960300041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Critically+ill+patients+with+the+Middle+East+respiratory+syndrome%3A+a+multicenter+retrospective+cohort+study.&amp;publication_year=2017&amp;journal=Crit+Care+Med&amp;pages=1683-1695&amp;doi=10.1097%2FCCM.0000000000002621&amp;pmid=28787295" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. <em>Lancet Infect Dis</em> 2014;14:1090-1095.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(14)70920-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25278221/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343743700034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ribavirin+and+interferon+alfa-2a+for+severe+Middle+East+respiratory+syndrome+coronavirus+infection%3A+a+retrospective+cohort+study.&amp;publication_year=2014&amp;journal=Lancet+Infect+Dis&amp;pages=1090-1095&amp;doi=10.1016%2FS1473-3099%2814%2970920-X&amp;pmid=25278221" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. <em>Lancet Infect Dis</em> 2013;13:752-761.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(13)70204-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23891402/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000323465900020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemiological%2C+demographic%2C+and+clinical+characteristics+of+47+cases+of+Middle+East+respiratory+syndrome+coronavirus+disease+from+Saudi+Arabia%3A+a+descriptive+study.&amp;publication_year=2013&amp;journal=Lancet+Infect+Dis&amp;pages=752-761&amp;doi=10.1016%2FS1473-3099%2813%2970204-4&amp;pmid=23891402" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. <em>Clin Infect Dis</em> 2020;70:1837-1844.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciz544" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31925415/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000537513500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ribavirin+and+interferon+therapy+for+critically+ill+patients+with+Middle+East+respiratory+syndrome%3A+a+multicenter+observational+study.&amp;publication_year=2020&amp;journal=Clin+Infect+Dis&amp;pages=1837-1844&amp;doi=10.1093%2Fcid%2Fciz544&amp;pmid=31925415" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Kain T, Lindsay PJ, Adhikari NKJ, Arabi YM, Van Kerkhove MD, Fowler RA. Pharmacologic treatments and supportive care for Middle East respiratory syndrome. <em>Emerg Infect Dis</em> 2020;26:1102-1112.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid2606.200037" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32213260/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000541513900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacologic+treatments+and+supportive+care+for+Middle+East+respiratory+syndrome.&amp;publication_year=2020&amp;journal=Emerg+Infect+Dis&amp;pages=1102-1112&amp;doi=10.3201%2Feid2606.200037&amp;pmid=32213260" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. <em>Thorax</em> 2004;59:252-256.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/thorax.2003.012658" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14985565/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000189217200016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Role+of+lopinavir%2Fritonavir+in+the+treatment+of+SARS%3A+initial+virological+and+clinical+findings.&amp;publication_year=2004&amp;journal=Thorax&amp;pages=252-256&amp;doi=10.1136%2Fthorax.2003.012658&amp;pmid=14985565" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and observational data on SARS and MERS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] who were treated with ribavirin alone. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. <em>Sci Rep</em> 2013;3:1686-1686.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/srep01686" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23594967/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000317643300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+novel+%CE%B2+coronavirus+replication+by+a+combination+of+interferon-%CE%B12b+and+ribavirin.&amp;publication_year=2013&amp;journal=Sci+Rep&amp;pages=1686-1686&amp;doi=10.1038%2Fsrep01686&amp;pmid=23594967" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and observational data on SARS and MERS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] rhesus macaque model of MERS-CoV infection. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. <em>Nat Med</em> 2013;19:1313-1317.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm.3362" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24013700/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325531700031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+with+interferon-%CE%B12b+and+ribavirin+improves+outcome+in+MERS-CoV-infected+rhesus+macaques.&amp;publication_year=2013&amp;journal=Nat+Med&amp;pages=1313-1317&amp;doi=10.1038%2Fnm.3362&amp;pmid=24013700" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and observational data on SARS and MERS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] rhesus macaque model of MERS-CoV infection. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV) — possible lessons from a systematic review of SARS-CoV therapy. <em>Int J Infect Dis</em> 2013;17(10):e792-8.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ijid.2013.07.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23993766/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000324476200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Therapeutic+options+for+Middle+East+respiratory+syndrome+coronavirus+%28MERS-CoV%29+%E2%80%94+possible+lessons+from+a+systematic+review+of+SARS-CoV+therapy.&amp;publication_year=2013&amp;journal=Int+J+Infect+Dis&amp;pages=e792-8&amp;doi=10.1016%2Fj.ijid.2013.07.002&amp;pmid=23993766" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. <em>PLoS Med</em> 2006;3(9):e343-e343.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.0030343" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16968120/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000241923800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS%3A+systematic+review+of+treatment+effects.&amp;publication_year=2006&amp;journal=PLoS+Med&amp;pages=e343-e343&amp;doi=10.1371%2Fjournal.pmed.0030343&amp;pmid=16968120" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. <em>J Gen Virol</em> 2014;95:571-577.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1099/vir.0.061911-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24323636/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000338177500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interferon-%CE%B2+and+mycophenolic+acid+are+potent+inhibitors+of+Middle+East+respiratory+syndrome+coronavirus+in+cell-based+assays.&amp;publication_year=2014&amp;journal=J+Gen+Virol&amp;pages=571-577&amp;doi=10.1099%2Fvir.0.061911-0&amp;pmid=24323636" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] rhesus macaque model of MERS-CoV infection. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] interferon agents tested in vitro. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Chan JFW, Chan K-H, Kao RYT, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. <em>J Infect</em> 2013;67:606-616.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jinf.2013.09.029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24096239/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000326588400012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Broad-spectrum+antivirals+for+the+emerging+Middle+East+respiratory+syndrome+coronavirus.&amp;publication_year=2013&amp;journal=J+Infect&amp;pages=606-616&amp;doi=10.1016%2Fj.jinf.2013.09.029&amp;pmid=24096239" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. <em>Antimicrob Agents Chemother</em> 2014;58:4875-4884.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.03011-14" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24841269/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000339259200073" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Screening+of+an+FDA-approved+compound+library+identifies+four+small-molecule+inhibitors+of+Middle+East+respiratory+syndrome+coronavirus+replication+in+cell+culture.&amp;publication_year=2014&amp;journal=Antimicrob+Agents+Chemother&amp;pages=4875-4884&amp;doi=10.1128%2FAAC.03011-14&amp;pmid=24841269" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. <em>J Infect Dis</em> 2015;212:1904-1913.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jiv392" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26198719/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000368671500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+with+lopinavir%2Fritonavir+or+interferon-%CE%B21b+improves+outcome+of+MERS-CoV+infection+in+a+nonhuman+primate+model+of+common+marmoset.&amp;publication_year=2015&amp;journal=J+Infect+Dis&amp;pages=1904-1913&amp;doi=10.1093%2Finfdis%2Fjiv392&amp;pmid=26198719" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. <em>Trials</em> 2018;19:81-81.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13063-017-2427-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29382391/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423823900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+Middle+East+respiratory+syndrome+with+a+combination+of+lopinavir-ritonavir+and+interferon-%CE%B21b+%28MIRACLE+trial%29%3A+study+protocol+for+a+randomized+controlled+trial.&amp;publication_year=2018&amp;journal=Trials&amp;pages=81-81&amp;doi=10.1186%2Fs13063-017-2427-0&amp;pmid=29382391" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] plan have been published previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Supplementary Appendix. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] data according to the published schedule. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] administered during the trial period. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] had completed 90 days of follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] Prespecified subgroup analyses </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] lopinavir–ritonavir as a suspension. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Arabi YM, Asiri AY, Assiri AM, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. <em>Trials</em> 2020;21:8-8.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13063-019-3846-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31900204/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000513539700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+Middle+East+respiratory+syndrome+with+a+combination+of+lopinavir%2Fritonavir+and+interferon-%CE%B21b+%28MIRACLE+trial%29%3A+statistical+analysis+plan+for+a+recursive+two-stage+group+sequential+randomized+controlled+trial.&amp;publication_year=2020&amp;journal=Trials&amp;pages=8-8&amp;doi=10.1186%2Fs13063-019-3846-x&amp;pmid=31900204" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] plan have been published previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] had completed 90 days of follow-up. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the statistical analysis plan (Table S4). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the published statistical analysis plan. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] of the adaptive design of the trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] Prespecified subgroup analyses </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] was one-sided with a type I error of 2.5%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] we reported the false discovery rate. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>i [...] in power over the traditional approach. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Chang M. Adaptive design theory and implementation using SAS and R. 2nd ed. Boca Raton, FL: Chapman &amp; Hall/CRC Press, 2014:153-180.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Chang+M.+Adaptive+design+theory+and+implementation+using+SAS+and+R.+2nd+ed.+Boca+Raton%2C+FL%3A+Chapman+%26+Hall%2FCRC+Press%2C+2014%3A153-180." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the published statistical analysis plan. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of the adaptive design of the trial. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r19-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] power than the traditional crude approach. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] in power over the traditional approach. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. <em>J R Stat Soc B</em> 1995;57:289-300.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.2517-6161.1995.tb02031.x" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1995QE45300017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Controlling+the+false+discovery+rate%3A+a+practical+and+powerful+approach+to+multiple+testing.&amp;publication_year=1995&amp;journal=J+R+Stat+Soc+B&amp;pages=289-300&amp;doi=10.1111%2Fj.2517-6161.1995.tb02031.x" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Katzen J, Kohn R, Houk JL, Ison MG. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. <em>Clin Infect Dis</em> 2019;69:52-58.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciy860" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30304487/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000485166800007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+oseltamivir+after+hospital+admission+is+associated+with+shortened+hospitalization%3A+a+5-year+analysis+of+oseltamivir+timing+and+clinical+outcomes.&amp;publication_year=2019&amp;journal=Clin+Infect+Dis&amp;pages=52-58&amp;doi=10.1093%2Fcid%2Fciy860&amp;pmid=30304487" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <em>Lancet Respir Med</em> 2014;2:395-404.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(14)70041-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24815805/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336716300022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+neuraminidase+inhibitors+in+reducing+mortality+in+patients+admitted+to+hospital+with+influenza+A+H1N1pdm09+virus+infection%3A+a+meta-analysis+of+individual+participant+data.&amp;publication_year=2014&amp;journal=Lancet+Respir+Med&amp;pages=395-404&amp;doi=10.1016%2FS2213-2600%2814%2970041-4&amp;pmid=24815805" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Hernu R, Chroboczek T, Madelaine T, et al. Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysis. <em>Intensive Care Med</em> 2018;44:257-260.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00134-017-4953-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29026934/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425330000020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+oseltamivir+therapy+improves+the+outcome+in+critically+ill+patients+with+influenza%3A+a+propensity+analysis.&amp;publication_year=2018&amp;journal=Intensive+Care+Med&amp;pages=257-260&amp;doi=10.1007%2Fs00134-017-4953-3&amp;pmid=29026934" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Chan PKS, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. <em>J Infect Dis</em> 2012;206:1359-1366.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jis509" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22927451/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309930700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determinants+of+antiviral+effectiveness+in+influenza+virus+A+subtype+H5N1.&amp;publication_year=2012&amp;journal=J+Infect+Dis&amp;pages=1359-1366&amp;doi=10.1093%2Finfdis%2Fjis509&amp;pmid=22927451" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <em>Lancet</em> 2020;395:1569-1578.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)31022-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32423584/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000536542900023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Remdesivir+in+adults+with+severe+COVID-19%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+multicentre+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1569-1578&amp;doi=10.1016%2FS0140-6736%2820%2931022-9&amp;pmid=32423584" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. <em>N Engl J Med</em> 2020;382:1787-1799.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_6_27_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2015294&amp;key=10.1056%2FNEJMoa2001282&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32187464/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000533411000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+trial+of+lopinavir%E2%80%93ritonavir+in+adults+hospitalized+with+severe+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1787-1799&amp;doi=10.1056%2FNEJMoa2001282&amp;pmid=32187464" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Best BM, Capparelli EV, Diep H, et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. <em>J Acquir Immune Defic Syndr</em> 2011;58:385-391.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0b013e318232b057" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21876444/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296920900015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetics+of+lopinavir%2Fritonavir+crushed+versus+whole+tablets+in+children.&amp;publication_year=2011&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=385-391&amp;doi=10.1097%2FQAI.0b013e318232b057&amp;pmid=21876444" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir. June 29, 2020 (<a href="https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf">https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement-29062020_final.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Statement+from+the+Chief+Investigators+of+the+Randomised+Evaluation+of+COVid-19+thERapY+%28RECOVERY%29+Trial+on+lopinavir-ritonavir.+June+29%2C+2020+%28https%3A%2F%2Fwww.recoverytrial.net%2Ffiles%2Flopinavir-ritonavir-recovery-statement-29062020_final.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. July 4, 2020 (<a href="https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19">https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=World+Health+Organization.+WHO+discontinues+hydroxychloroquine+and+lopinavir%2Fritonavir+treatment+arms+for+COVID-19.+July+4%2C+2020+%28https%3A%2F%2Fwww.who.int%2Fnews-room%2Fdetail%2F04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Cameron MJ, Kelvin AA, Leon AJ, et al. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. <em>PLoS One</em> 2012;7(9):e45842-e45842.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0045842" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23029269/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309554700077" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lack+of+innate+interferon+responses+during+SARS+coronavirus+infection+in+a+vaccination+and+reinfection+ferret+model.&amp;publication_year=2012&amp;journal=PLoS+One&amp;pages=e45842-e45842&amp;doi=10.1371%2Fjournal.pone.0045842&amp;pmid=23029269" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. <em>PLoS One</em> 2009;4(12):e8342-e8342.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0008342" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20020050/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272834200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+SARS+Coronavirus+3a+protein+causes+endoplasmic+reticulum+stress+and+induces+ligand-independent+downregulation+of+the+type+1+interferon+receptor.&amp;publication_year=2009&amp;journal=PLoS+One&amp;pages=e8342-e8342&amp;doi=10.1371%2Fjournal.pone.0008342&amp;pmid=20020050" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Siu K-L, Chan C-P, Kok K-H, Woo PC-Y, Jin D-Y. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. <em>Cell Mol Immunol</em> 2014;11:141-149.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/cmi.2013.61" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24509444/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000332471400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suppression+of+innate+antiviral+response+by+severe+acute+respiratory+syndrome+coronavirus+M+protein+is+mediated+through+the+first+transmembrane+domain.&amp;publication_year=2014&amp;journal=Cell+Mol+Immunol&amp;pages=141-149&amp;doi=10.1038%2Fcmi.2013.61&amp;pmid=24509444" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Wathelet MG, Orr M, Frieman MB, Baric RS. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. <em>J Virol</em> 2007;81:11620-11633.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JVI.00702-07" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17715225/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000250417400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Severe+acute+respiratory+syndrome+coronavirus+evades+antiviral+signaling%3A+role+of+nsp1+and+rational+design+of+an+attenuated+strain.&amp;publication_year=2007&amp;journal=J+Virol&amp;pages=11620-11633&amp;doi=10.1128%2FJVI.00702-07&amp;pmid=17715225" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Lee JY, Bae S, Myoung J. Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design. <em>J Microbiol</em> 2019;57:803-811.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12275-019-9272-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31452044/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000482929400010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Middle+East+respiratory+syndrome+coronavirus-encoded+ORF8b+strongly+antagonizes+IFN-%CE%B2+promoter+activation%3A+its+implication+for+vaccine+design.&amp;publication_year=2019&amp;journal=J+Microbiol&amp;pages=803-811&amp;doi=10.1007%2Fs12275-019-9272-7&amp;pmid=31452044" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Yang Y, Ye F, Zhu N, et al. Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets. <em>Sci Rep</em> 2015;5:17554-17554.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/srep17554" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26631542/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365690100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Middle+East+respiratory+syndrome+coronavirus+ORF4b+protein+inhibits+type+I+interferon+production+through+both+cytoplasmic+and+nuclear+targets.&amp;publication_year=2015&amp;journal=Sci+Rep&amp;pages=17554-17554&amp;doi=10.1038%2Fsrep17554&amp;pmid=26631542" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. <em>Cell</em> 2020;181:1036-1045.e9.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2020.04.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32416070/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000537399500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Imbalanced+host+response+to+SARS-CoV-2+drives+development+of+COVID-19.&amp;publication_year=2020&amp;journal=Cell&amp;pages=1036-1045.e9&amp;doi=10.1016%2Fj.cell.2020.04.026&amp;pmid=32416070" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. <em>Science</em> 2020;369:718-724.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abc6027" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32661059/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559184400051" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impaired+type+I+interferon+activity+and+inflammatory+responses+in+severe+COVID-19+patients.&amp;publication_year=2020&amp;journal=Science&amp;pages=718-724&amp;doi=10.1126%2Fscience.abc6027&amp;pmid=32661059" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <em>Science</em> 2020 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd4570" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32972995/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077200034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inborn+errors+of+type+I+IFN+immunity+in+patients+with+life-threatening+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;doi=10.1126%2Fscience.abd4570&amp;pmid=32972995" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="core-r39" class="citations"><div class="citation"><div class="citation-content">Bastard P, Rosen LB, Zhang Q, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. <em>Science</em> 2020 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd4585" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32972996/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581077200035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Auto-antibodies+against+type+I+IFNs+in+patients+with+life-threatening+COVID-19.&amp;publication_year=2020&amp;journal=Science&amp;doi=10.1126%2Fscience.abd4585&amp;pmid=32972996" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="core-r40" class="citations"><div class="citation"><div class="citation-content">Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. <em>Lancet</em> 2020;395:1695-1704.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r40-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)31042-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32401715/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561610000023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple+combination+of+interferon+beta-1b%2C+lopinavir-ritonavir%2C+and+ribavirin+in+the+treatment+of+patients+admitted+to+hospital+with+COVID-19%3A+an+open-label%2C+randomised%2C+phase+2+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1695-1704&amp;doi=10.1016%2FS0140-6736%2820%2931042-4&amp;pmid=32401715" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r40-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r40-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] treatment with lopinavir–ritonavir alone. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r42" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] concerns about its proinflammatory effects. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">41.</div><div id="core-r41" class="citations"><div class="citation"><div class="citation-content">Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV–infected mice. <em>Cell Host Microbe</em> 2016;19:181-193.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.chom.2016.01.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26867177/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000369840100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dysregulated+type+I+interferon+and+inflammatory+monocyte-macrophage+responses+cause+lethal+pneumonia+in+SARS-CoV%E2%80%93infected+mice.&amp;publication_year=2016&amp;journal=Cell+Host+Microbe&amp;pages=181-193&amp;doi=10.1016%2Fj.chom.2016.01.007&amp;pmid=26867177" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">42.</div><div id="core-r42" class="citations"><div class="citation"><div class="citation-content">Channappanavar R, Fehr AR, Zheng J, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. <em>J Clin Invest</em> 2019;129:3625-3639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI126363" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31355779/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000484368600022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IFN-I+response+timing+relative+to+virus+replication+determines+MERS+coronavirus+infection+outcomes.&amp;publication_year=2019&amp;journal=J+Clin+Invest&amp;pages=3625-3639&amp;doi=10.1172%2FJCI126363&amp;pmid=31355779" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">43.</div><div id="core-r43" class="citations"><div class="citation"><div class="citation-content">Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. <em>Int Immunopharmacol</em> 2020 August 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r44"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.intimp.2020.106903" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32862111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000588166300127" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interferon+%CE%B2-1b+in+treatment+of+severe+COVID-19%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=Int+Immunopharmacol&amp;doi=10.1016%2Fj.intimp.2020.106903&amp;pmid=32862111" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">44.</div><div id="core-r44" class="citations"><div class="citation"><div class="citation-content">Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe Covid-19. <em>Antimicrob Agents Chemother</em> 2020;64(9):e01061-20-e01061-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r44"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.01061-20" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32661006/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000680923300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized+clinical+trial+of+the+efficacy+and+safety+of+interferon+%CE%B2-1a+in+treatment+of+severe+Covid-19.&amp;publication_year=2020&amp;journal=Antimicrob+Agents+Chemother&amp;pages=e01061-20-e01061-20&amp;doi=10.1128%2FAAC.01061-20&amp;pmid=32661006" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">45.</div><div id="core-r45" class="citations"><div class="citation"><div class="citation-content">Synairgen. Synairgen announces positive results from trial of SNG001 in hospitalised Covid-19 patients. July 20, 2020 (<a href="https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf">https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Synairgen.+Synairgen+announces+positive+results+from+trial+of+SNG001+in+hospitalised+Covid-19+patients.+July+20%2C+2020+%28https%3A%2F%2Fwww.synairgen.com%2Fwp-content%2Fuploads%2F2020%2F07%2F200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">46.</div><div id="core-r46" class="citations"><div class="citation"><div class="citation-content">Bellingan G, Maksimow M, Howell DC, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. <em>Lancet Respir Med</em> 2014;2:98-107.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r46-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(13)70259-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24503265/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000333768500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+effect+of+intravenous+interferon-beta-1a+%28FP-1201%29+on+lung+CD73+expression+and+on+acute+respiratory+distress+syndrome+mortality%3A+an+open-label+study.&amp;publication_year=2014&amp;journal=Lancet+Respir+Med&amp;pages=98-107&amp;doi=10.1016%2FS2213-2600%2813%2970259-5&amp;pmid=24503265" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r46-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r48-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with moderate-to-severe ARDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r46-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] lower 28-day mortality than use of placebo. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">47.</div><div id="core-r47" class="citations"><div class="citation"><div class="citation-content">Ranieri VM, Pettilä V, Karvonen MK, et al. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. <em>JAMA</em> 2020;323:725-733.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r47-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2019.22525" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32065831/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000518617500022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+intravenous+interferon+%CE%B2-1a+on+death+and+days+free+from+mechanical+ventilation+among+patients+with+moderate+to+severe+acute+respiratory+distress+syndrome%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=725-733&amp;doi=10.1001%2Fjama.2019.22525&amp;pmid=32065831" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r47-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r48-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with moderate-to-severe ARDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r47-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] number of ventilator-free days at day 28). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r48-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] beta-1a without glucocorticoids was not. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">48.</div><div id="core-r48" class="citations"><div class="citation"><div class="citation-content">Shankar-Hari M, Calfee CS. Lack of clinical benefit of interferon β-1a among patients with severe acute respiratory distress syndrome: time to overhaul drug trials in ARDS? <em>JAMA</em> 2020 February 17 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r48-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2019.22524" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32065830/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000518617500018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lack+of+clinical+benefit+of+interferon+%CE%B2-1a+among+patients+with+severe+acute+respiratory+distress+syndrome%3A+time+to+overhaul+drug+trials+in+ARDS%3F&amp;publication_year=2020&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2019.22524&amp;pmid=32065830" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r48-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r48-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with moderate-to-severe ARDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r48-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] beta-1a without glucocorticoids was not. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">49.</div><div id="core-r49" class="citations"><div class="citation"><div class="citation-content">Jalkanen J, Pettilä V, Huttunen T, Hollmén M, Jalkanen S. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. <em>Intensive Care Med</em> 2020 May 19 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r49"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00134-020-06086-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32430515/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534200300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glucocorticoids+inhibit+type+I+IFN+beta+signaling+and+the+upregulation+of+CD73+in+human+lung.&amp;publication_year=2020&amp;journal=Intensive+Care+Med&amp;doi=10.1007%2Fs00134-020-06086-3&amp;pmid=32430515" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">50.</div><div id="core-r50" class="citations"><div class="citation"><div class="citation-content">Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. <em>N Engl J Med</em>.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r50"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_6_51_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2015294&amp;key=10.1056%2FNEJMoa2021436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000623807600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dexamethasone+in+hospitalized+patients+with+Covid-19+%E2%80%94+preliminary+report.&amp;journal=N+Engl+J+Med&amp;doi=10.1056%2FNEJMoa2021436" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">51.</div><div id="core-r51" class="citations"><div class="citation"><div class="citation-content">Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. <em>Nature</em> 2020;585:273-276.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r51"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-020-2423-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32516797/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000565516300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+benefit+of+remdesivir+in+rhesus+macaques+infected+with+SARS-CoV-2.&amp;publication_year=2020&amp;journal=Nature&amp;pages=273-276&amp;doi=10.1038%2Fs41586-020-2423-5&amp;pmid=32516797" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Staten Island, New York</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/726362/gastroenterology-inflammatory-bowel-disease-staten-island-university-hospital/?query=fjwp&amp;rid=3059">Gastroenterology - Inflammatory Bowel Disease, Staten Island University Hospital</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881587/hospitalist/?query=fjwp&amp;rid=165114">Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> Indianapolis, Indiana</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883800/academic-neuroimmunologist-opportunity-with-nationally-recognized-neuroscience-center/?query=fjwf&amp;rid=227332">Academic Neuroimmunologist opportunity with nationally recognized Neuroscience Center</a></div></div><div class="nejm-widget_item"><div><span> Lodi, California</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880022/physician-cardiology-invasive-lodi-ca-/?query=fjwf&amp;rid=845677">Physician, Cardiology-Invasive (Lodi, CA)</a></div></div><div class="nejm-widget_item"><div><span> Roseville, California</span></div><div><span>Endocrinology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889326/physician-endocrinology-roseville-ca-/?query=fjwf&amp;rid=845679">Physician, Endocrinology (Roseville, CA)</a></div></div><div class="nejm-widget_item"><div><span> California</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893210/outpatient-family-medicine-in-san-diego-ca-332k-base-pension-plan-available/?query=fjwf&amp;rid=5263">Outpatient Family Medicine in San Diego, CA | 332k Base | Pension Plan Available</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2015294&amp;pubId=41289121&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6515ae59fa3fc-GRU">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6515ae59fa3fc-GRU"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6515ae59fa3fc-GRU"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$983575066$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$983575066$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$983575066$--></div></div><div class="mlt-body"><!--?lit$983575066$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$983575066$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$983575066$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$983575066$-->Feb 25, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2021436?query=recirc_Semantic" target="_self">Dexamethasone in Hospitalized Patients with Covid-19</a></div><div class="mlt-article-authors"><!--?lit$983575066$-->The RECOVERY Collaborative Group</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$983575066$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$983575066$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$983575066$-->Feb 10, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2117814?query=recirc_Semantic" target="_self">Molnupiravir — A Step toward Orally Bioavailable Therapies for Covid-19</a></div><div class="mlt-article-authors"><!--?lit$983575066$-->R. Whitley</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/perspective" target="_self"><!--?lit$983575066$-->Perspective</a> <span class="mlt-article-site-label"><!--?lit$983575066$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$983575066$-->Aug 05, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMp2102256?query=recirc_Semantic" target="_self">Contact Tracing for Covid-19 — A Digital Inoculation against Future Pandemics</a></div><div class="mlt-article-authors"><!--?lit$983575066$-->J. O’Connell and D.T. O’Keeffe</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/special-report" target="_self"><!--?lit$983575066$-->Special Report</a> <span class="mlt-article-site-label"><!--?lit$983575066$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$983575066$-->Sep 10, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMsr2022263?query=recirc_Semantic" target="_self">Rapid Scaling Up of Covid-19 Diagnostic Testing in the United States — The NIH RADx Initiative</a></div><div class="mlt-article-authors"><!--?lit$983575066$-->B.J. Tromberg and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$983575066$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$983575066$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$983575066$-->Feb 09, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2209760?query=recirc_Semantic" target="_self">Early Treatment with Pegylated Interferon Lambda for Covid-19</a></div><div class="mlt-article-authors"><!--?lit$983575066$-->G. Reis and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2015294?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2015294" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2015294.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2015294"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa1913590" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra2023935" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Sensory Ganglionopathy</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2015294_f1.jpg"><img src="/cms/10.1056/NEJMoa2015294/asset/fdebc372-176d-4a6d-a967-d5590567d359/assets/images/large/nejmoa2015294_f1.jpg" height="2700" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Probability of Survival and Subgroup Analyses.</div><div class="notes"><div role="doc-footnote">Panel A shows a Kaplan–Meier survival analysis involving all the patients enrolled in the trial. Panel B shows the results of prespecified subgroup analyses of the primary outcome (90-day all-cause mortality). Two-sided P values for interaction are reported. The false discovery rate (FDR) accounts for multiplicity by calculating the expected proportion of tests with false positives at a specified rank of a set of tests. The size of each square is proportional to the subgroup sample size. Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores indicating more severe disease and a higher risk of death.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Interventions and Cointerventions during the Trial Period.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">90-Day All-Cause Mortality (Primary Outcome).</div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t4" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 4</div><div class="fv__item__description"><figcaption><div class="caption">Secondary Outcomes.<a href="#fv-t4fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/17" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 17</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 22, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2016272" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R. Foà and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 22, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2012047" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">E.S. Dellon and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 22, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1913590" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">B.C. Trapnell and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2015294%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2015294&amp;pubId=41289121&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2015294%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2015294&amp;pubId=41289121&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id01947013012766291" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6515ae59fa3fc-GRU" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6515ae59fa3fc-GRU" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6515ae59fa3fc-GRU"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6515ae59fa3fc-GRU"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6515ae59fa3fc-GRU"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6515ae59fa3fc-GRU"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6515ae59fa3fc-GRU">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6515ae59fa3fc-GRU">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6515ae59fa3fc-GRU"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6515ae59fa3fc-GRU"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6515acea3a3fc',t:'MTc0OTUzMTc2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6515acea3a3fc&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-transactionid="pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" id="captureIFrame_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" target="captureIFrame_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="capture_screen"><input id="capture_signIn_js_version_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="js_version"><input id="capture_signIn_transactionId_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" type="hidden" class="capture_transactionId_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="capture_transactionId"><input id="capture_signIn_form_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="form"><input id="capture_signIn_flow_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="flow"><input id="capture_signIn_client_id_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="client_id"><input id="capture_signIn_redirect_uri_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="redirect_uri"><input id="capture_signIn_response_type_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="response_type"><input id="capture_signIn_flow_version_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="flow_version"><input id="capture_signIn_settings_version_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="settings_version"><input id="capture_signIn_locale_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="locale"><input id="capture_signIn_recaptcha_version_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_pn73jj5hfzfaex5f5zra2u9mjesvic49rv5t34nb" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><mua-dpfsjqzlkxds></mua-dpfsjqzlkxds><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2015294?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script></body></html>